

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 401/06, 401/12, 401/14, A61K 31/445, 31/47, A61P 31/04		A1	(11) International Publication Number: WO 00/43383
			(43) International Publication Date: 27 July 2000 (27.07.00)
(21) International Application Number: PCT/EP00/00350			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 17 January 2000 (17.01.00)			
(30) Priority Data: 9901236.1 20 January 1999 (20.01.99) GB 9923936.0 8 October 1999 (08.10.99) GB			
(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): DAVIES, David, Thomas [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). HENRY, Caroline, Joan [GB/GB]; SmitKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PEARSON, Neil, David [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).			
(74) Agent: VALENTINE, Jill, Barbara; SmithKline Beecham Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).			Published With international search report.
(54) Title: PIPERIDINYLQUINOLINES AS PROTEIN TYROSINE KINASE INHIBITORS			
(57) Abstract Piperidine derivatives, processes for making them and their use in methods of treatment of bacterial infections in mammals.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PIPERIDINYLQUINOLINES AS PROTEIN TYROSINE KINASE INHIBITORS

This invention relates to novel medicaments, being novel antibacterial compounds and compositions.

- 5 WO9217475, WO9802438, WO9703069 and WO9639145 disclose certain bicyclic heteroaromatic compounds having cholinesterase inhibitor, protein tyrosine kinase inhibitor, cell proliferation inhibitor and human epidermal growth factor receptor type 2 inhibitor activity.

- 10 This invention provides a method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment of an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof:



(I)

wherein:

one of Z¹, Z², Z³, Z⁴ and Z⁵ is N or CR^{1a} and the remainder are CH;

- 20 R¹ is selected from hydroxy; (C₁₋₆) alkoxy optionally substituted by (C₁₋₆)alkoxy, amino, piperidyl, guanidino or amidino optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups, NH₂CO, hydroxy, thiol, (C₁₋₆)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋₆)alkylsulphonyloxy; (C₁₋₆)alkoxy-substituted (C₁₋₆)alkyl; halogen; (C₁₋₆)alkyl; (C₁₋₆)alkylthio; trifluoromethyl; nitro; azido; acyl; acyloxy; acylthio; (C₁₋₆)alkylsulphonyl; (C₁₋₆)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups, or when one of Z¹, Z², Z³, Z⁴ and Z⁵ is N, R¹ may instead be hydrogen;

30

R^{1a} is selected from hydrogen and the groups listed above for R¹;

R³ is in the 2- or 3-position and is:

- carboxy; (C₁₋₆)alkoxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, trifluoromethylsulphonyl, (C₁₋₆)alkenylsulphonyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R¹⁰; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R¹⁰; or 5-oxo-1,2,4-oxadiazol-3-yl; or
- 10 R³ is in the 2- or 3-position and is (C₁₋₄)alkyl or ethenyl substituted with any of the groups listed above for R³ and 0 to 2 groups R¹² independently selected from:
- thiol; halogen; (C₁₋₆)alkylthio; trifluoromethyl; azido; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; (C₂₋₆)alkenylcarbonyl; hydroxy optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl or aminocarbonyl
- 15 wherein the amino group is optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylcarbonyl or (C₂₋₆)alkenylcarbonyl; amino optionally mono- or disubstituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, (C₂₋₆)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted
- 20 by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; oxo; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or (C₁₋₆)aminosulphonyl wherein the amino group is optionally
- 25 substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl;
- provided that when R³ is disubstituted with hydroxy or amino and carboxy containing substituents these may optionally together form a cyclic ester or amide linkage,
- 30 respectively;
- and provided that R³ is other than (C₁₋₄)alkyl or ethenyl substituted by (C₁₋₆)alkoxycarbonyl or aminocarbonyl optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl and 0 to 2 groups R¹²;
- 35

6)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl or (C₁₋₆)alkenyl and optionally further substituted by (C₁₋₆)alkyl or (C₁₋₆)alkenyl;

provided that A and B cannot both be selected from NR¹¹, O and S(O)_x and when one of
5 A and B is CO the other is not CO, O or S(O)_x.

In one aspect the invention provides a method according to the invention wherein in compounds of formula (I) R¹ and R^{1a} are selected from the groups listed above other than trifluoromethyl.

10 The invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.

The invention also provides a pharmaceutical composition for use in the treatment of bacterial infections in mammals comprising a compound of formula (I), or a
15 pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.

Preferably Z⁵ is CH or N and Z¹-Z⁴ are each CH.

In a preferred aspect, when A is CH₂ or CHOH and B is CH₂ or A is CH₂ and B is CHOH and n is 1 the substituents at the 3- and 4-position of the piperidine ring are cis.

When R¹ or R^{1a} is substituted alkoxy it is preferably C₂₋₆ alkoxy substituted
20 by optionally N-substituted amino, guanidino or amidino, or C₁₋₆alkoxy substituted by piperidyl. Suitable examples of R¹ alkoxy include methoxy, n-propyloxy, i-butyloxy, aminoethyloxy, aminopropyloxy, aminopentyloxy, guanidinopropyloxy, piperidin-4-ylmethyloxy, phthalimido pentyloxy or 2-aminocarbonylprop-2-oxy. Preferably R¹ is methoxy, amino- or guanidino-(C₃₋₅)alkyloxy, guanidino(C₃₋₅)alkyloxy, piperidyl(C₃₋₅)alkyloxy, nitro or fluoro, most preferably methoxy.
25

R^{1a} is preferably hydrogen.

R³ preferably contains carboxy, cyano or 2-oxo-oxazolidinyl optionally substituted by R¹⁰.

Where R³ is substituted alkyl it is preferably substituted methyl.

30 Examples of R³ include CO₂H, CH₂CO₂H, (CH₂)₂CO₂H, (CH₂)₂CN, CONH₂, CH(OH)CH₂CN, CH(OH)CH₂CO₂H, CH=CHCO₂H or 2-oxo-oxazolidinyl.

R³ is preferably in the 3-position.

R³ is most preferably CH₂CO₂H or 2-oxo-oxazolidinyl.

Preferably A is NH, NCH₃, O, CH₂, CHOH, CH(NH₂), C(Me)(OH) or CH(Me).

35 Preferably B is CH₂, CHOH or CO.

Preferably n is 0 or 1.

More preferably:

when A is NH, B is CO and n is 1 or 0;

when A is O, B is CH₂ and n is 1 or 0;

when A is CH₂ or CH₂OH, B is CH₂, and n is 1 or 0;

when A is NCH₃, CH(NH₂), C(Me)(OH) or CH(Me), B is CH₂ and n is 1;

- 5 when A is CR⁶R⁷ and B CR⁸R⁹ and R⁶ and R⁸ together represent -O- and R⁷ and R⁹ are both hydrogen and n is 1.

AB(CH₂)_n is most preferably (CH₂)₃.

- Suitable groups R⁴ include n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-dodecyl, methoxybutyl, phenylethyl, phenylpropyl or 3-phenyl-prop-2-en-yl optionally
10 substituted on the phenyl ring, 3-benzoylpropyl, 4-benzoylbutyl, 3-pyridylmethyl, 3-(4-fluorobenzoyl)propyl, cyclohexylmethyl, cyclobutylmethyl, t-butoxycarbonylaminomethyl and phenoxyethyl.

- Preferably R⁴ is (C₅₋₁₀)alkyl, unsubstituted phenyl(C₂₋₃)alkyl or unsubstituted phenyl(C₃₋₄)alkenyl, more preferably hexyl, heptyl, 5-methylhexyl, 6-methyl heptyl, 3-
15 phenyl-prop-2-en-yl or 3-phenylpropyl, most preferably n-heptyl.

Most preferably R⁵ is unbranched at the α and, where appropriate, β positions.

Halo or halogen includes fluoro, chloro, bromo and iodo.

- The term 'heterocyclic' as used herein includes aromatic and non-aromatic, single and fused, rings suitably containing up to four hetero-atoms in each ring selected from
20 oxygen, nitrogen and sulphur, which rings may be unsubstituted or substituted by, for example, up to three groups selected from optionally substituted amino, halogen, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, halo(C₁₋₆)alkyl, hydroxy, carboxy, carboxy salts, carboxy esters such as (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, aryl, and oxo groups. Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused
25 heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring. Compounds within the invention containing a heterocyclyl group may occur in two or more tautomeric forms depending on the nature of the heterocyclyl group; all such tautomeric forms are included within the scope of the invention.

- Where an amino group forms part of a single or fused non-aromatic heterocyclic ring as defined above suitable optional substituents in such substituted amino groups
30 include (C₁₋₆)alkyl optionally substituted by hydroxy, (C₁₋₆)alkoxy, thiol, (C₁₋₆)alkylthio, halo or trifluoromethyl, and amino-protecting groups such as acyl or (C₁₋₆)alkylsulphonyl groups.

The term 'heteroaryl' includes the aromatic heterocyclic groups referred to above.

- 35 Examples of heteroaryl groups include pyridyl, triazolyl, tetrazolyl, indolyl, thienyl, isoimidazolyl, thiazolyl, furanyl, quinolynyl, imidazolidinyl and benzothienyl.

When used herein the term 'aryl', includes phenyl and naphthyl, each optionally substituted with up to five, preferably up to three, groups selected from halogen, mercapto, (C₁₋₆)alkyl, phenyl, (C₁₋₆)alkoxy, hydroxy(C₁₋₆)alkyl, mercapto (C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, optionally substituted amino, nitro, carboxy, (C₁₋₆)alkylcarbonyloxy, (C₁₋₆)alkoxycarbonyl, formyl, or (C₁₋₆)alkylcarbonyl groups.

The term 'acyl' includes (C₁₋₆)alkoxycarbonyl, formyl or (C₁₋₆) alkylcarbonyl group.

Compounds of formula (I) wherein R³ is other than (C₁₋₆)alkoxycarbonyl; optionally substituted aminocarbonyl, CN or COOH, hereinafter 'compounds of formula (IA)' and pharmaceutically acceptable derivatives thereof are novel and as such form part of the invention.

The invention also provides a pharmaceutical composition comprising a compound of formula (IA), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.



Some of the compounds of this invention may be crystallised or recrystallised from solvents such as organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.

Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 59% of a compound of the formula (I) or salt thereof.

Pharmaceutically acceptable derivatives of the above-mentioned compounds of formula (I) include the free base form or their acid addition or quaternary ammonium salts, for example their salts with mineral acids e.g. hydrochloric, hydrobromic, sulphuric nitric or phosphoric acids, or organic acids, e.g. acetic, fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic, methanesulphonic, naphthalenesulphonic acid or tartaric acids. Compounds of formula (I) may also be prepared as the N-oxide. Compounds of formula (I) having a free carboxy group may also be prepared as an *in vivo* hydrolysable ester. The invention extends to all such derivatives.

Examples of suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming groups include those forming esters which break down readily in the human

body to leave the parent acid or its salt. Suitable groups of this type include those of part formulae (i), (ii), (iii), (iv) and (v):



5




wherein R^a is hydrogen, (C₁₋₆) alkyl, (C₃₋₇) cycloalkyl, methyl, or phenyl, R^b is (C₁₋₆) alkyl, (C₁₋₆) alkoxy, phenyl, benzyl, (C₃₋₇) cycloalkyl, (C₃₋₇) cycloalkyloxy, (C₁₋₆) alkyl (C₃₋₇) cycloalkyl, 1-amino (C₁₋₆) alkyl, or 1-(C₁₋₆ alkyl)amino (C₁₋₆) alkyl; or R^a and R^b together form a 1,2-phenylene group optionally substituted by one or two methoxy groups; R^c represents (C₁₋₆) alkylene optionally substituted with a methyl or ethyl group and R^d and R^e independently represent (C₁₋₆) alkyl; R^f represents (C₁₋₆) alkyl; R^g represents hydrogen or phenyl optionally substituted by up to three groups selected from halogen, (C₁₋₆) alkyl, or (C₁₋₆) alkoxy; Q is oxygen or NH; R^h is hydrogen or (C₁₋₆) alkyl; R^i is hydrogen, (C₁₋₆) alkyl optionally substituted by halogen, (C₂₋₆) alkenyl, (C₁₋₆) alkoxycarbonyl, aryl or heteroaryl; or R^h and R^i together form (C₁₋₆) alkylene; R^j represents hydrogen, (C₁₋₆) alkyl or (C₁₋₆) alkoxycarbonyl; and R^k represents (C₁₋₈) alkyl, (C₁₋₈) alkoxy, (C₁₋₆) alkoxy(C₁₋₆)alkoxy or aryl.

20 Examples of suitable *in vivo* hydrolysable ester groups include, for example, acyloxy(C₁₋₆)alkyl groups such as acetoxymethyl, pivaloyloxymethyl, α -acetoxylethyl, α -pivaloyloxyethyl, 1-(cyclohexylcarbonyloxy)prop-1-yl, and (1-aminoethyl)carbonyloxymethyl; (C₁₋₆)alkoxycarbonyloxy(C₁₋₆)alkyl groups, such as

- ethoxycarbonyloxymethyl, α -ethoxycarbonyloxyethyl and propoxycarbonyloxyethyl;
 di(C₁₋₆)alkylamino(C₁₋₆)alkyl especially di(C₁₋₄)alkylamino(C₁₋₄)alkyl groups such as
 dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl;
 2-((C₁₋₆)alkoxycarbonyl)-2-(C₂₋₆)alkenyl groups such as
 2-((isobutoxycarbonyl)pent-2-enyl and 2-(ethoxycarbonyl)but-2-enyl; lactone groups such
 as phthalidyl and dimethoxyphthalidyl.

A further suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming group is that of the formula:



10


wherein R^k is hydrogen, C₁₋₆ alkyl or phenyl.

R is preferably hydrogen.


- Certain of the above-mentioned compounds of formula (I) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures. The invention includes all such forms, in particular the pure isomeric forms. For examples the invention includes compound in which an A-B group CH(OH)-CH₂ is in either isomeric configuration, the *R*-isomer is preferred. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

- In a further aspect of the invention there is provided a process for preparing compounds of formula (IA), or a pharmaceutically acceptable derivative thereof, which process comprises:

- (a) reacting a compound of formula (IV) with a compound of formula (V):



(IV)




(V)

- wherein Z¹, Z², Z³, Z⁴ and Z⁵, m, n, R¹, R², R³ and R⁴ are as defined in formula (I), and X and Y may be the following combinations:

- (i) X is M and Y is CH₂CO₂R^x


- (ii) X is CO_2R^Y and Y is $\text{CH}_2\text{CO}_2\text{R}^X$
 (iii) one of X and Y is $\text{CH}=\text{SPh}_2$ and the other is CHO
 (iv) X is CH_3 and Y is CHO
 (v) X is CH_3 and Y is CO_2R^X
 5 (vi) X is $\text{CH}_2\text{CO}_2\text{R}^Y$ and Y is CO_2R^X
 (vii) X is $\text{CH}=\text{PR}^Z_3$ and Y is CHO
 (viii) X is CHO and Y is $\text{CH}=\text{PR}^Z_3$
 (ix) X is halogen and Y is $\text{CH}=\text{CH}_2$
 (x) one of X and Y is COW and the other is $\text{NHR}^{11'}$ or NCO
 10 (xi) one of X and Y is $(\text{CH}_2)_p\text{-V}$ and the other is $(\text{CH}_2)_q\text{NHR}^{11'}$, $(\text{CH}_2)_q\text{OH}$, $(\text{CH}_2)_q\text{SH}$ or $(\text{CH}_2)_q\text{SCOR}^X$ where $p+q=1$
 (xii) one of X and Y is CHO and the other is $\text{NHR}^{11'}$
 (xiii) one of X and Y is OH and the other is $-\text{CH}=\text{N}_2$
 in which V and W are leaving groups, R^X and R^Y are (C_{1-6}) alkyl and R^Z is aryl or (C_{1-6}) alkyl, or
 15 (xiv) X is NCO , Y is OH or NH_2 ;

(b) reacting a compound of formula (IV) with a compound of formula (Vb):




wherein $\text{Z}^1, \text{Z}^2, \text{Z}^3, \text{Z}^4$ and Z^5 , m, n, $\text{R}^1, \text{R}^2, \text{R}^3$ and R^4 are as defined in formula (I), X is $\text{CH}_2\text{NHR}^{11'}$ and Y is CHO or COW or X is CH_2OH and Y is $-\text{CH}=\text{N}_2$;

- 25 (c) rearranging a compound of formula (II):



to give a compound of formula (III) which is a compound of formula (I) where Z^1-Z^5 are CH, n is 1, A-B is COCH_2 and R^2 is H, or a compound of formula (VII) which is a compound of formula (I) where n is 1, A-B is CHOHCH_2 or CH_2CHOH and R^2 is H; or

- 5 (d) photooxygenating a compound of formula (VI):



- 10 in which Z^1-Z^5 are Z^1-Z^5 or groups convertible thereto, R^{11}, R^1, R^2, R^3 and R^4 are R^{11}, R^1, R^2, R^3 and R^4 or groups convertible thereto, and thereafter optionally or as necessary converting R^{11}, R^1, R^2, R^3 and R^4 to R^{11}, R^1, R^2, R^3 and R^4 , converting Z^1-Z^5 to Z^1-Z^5 , converting A-B to other A-B, interconverting R^{11}, R^1, R^2, R^3 and/or R^4 and forming a pharmaceutically acceptable derivative thereof.

15

Process variants (a)(i) and (a)(ii), (c) in certain aspects and (d) initially produce compounds of formula (I) where A-B is COCH_2 . The products of variants (c) and (d) have $n=1$.

- 20 Process variant (a)(iii) and (c) in other aspects initially produces compounds of formula (I) wherein A-B is CH_2CHOH or CHOHCH_2 .

Process variant (a)(iv) initially produces compounds of formula (I) wherein A-B is CH_2CHOH .

Process variants (a)(v) and (a)(vi), initially produce compounds of formula (I) wherein A-B is CH_2CO .

- 25 Process variants (a)(vii), (a)(viii) and (a)(ix) initially produce compounds where A-B is $\text{CH}=\text{CH}$.

Process variant (a)(x) initially produces compounds of formula (I) wherein A-B is CONHR^{11} or NHR^{11}CO .

- 30 Process variant (a)(xi) initially produces compounds of formula (I) wherein one of A and B is CH_2 and the other is NHR^{11} , O or S.

Process variant (a)(xii), initially produce compounds of formula (I) wherein A-B is $\text{CH}_2\text{NHR}^{11}$ or $\text{NHR}^{11}\text{CH}_2$.

Process variant (a)(xiii) initially produces compounds of formula (I) wherein A-B is OCH_2 or CH_2O .

Process variant (a)(xiv) initially produces compounds of formula (I) where A-B is NHC(O)NH or NHC(O)O.

Process variant (b) initially produces compounds of formula (I) wherein A is CH₂ and B is NHR¹¹ or O.

5 In process variant (a)(i) M is preferably an alkali metal, more preferably Li. The reaction is conducted in an aprotic solvent preferably THF, ether or benzene at -78 to 25°C. An analogous route is described in G. Grethe et al (1972) *Helv. Chimica.Acta.*, 55, 1044.

10 In process variant (a)(ii) the process is two step: firstly a condensation using a base, preferably sodium hydride or alkoxide, sodamide, alkyl lithium or lithium dialkylamide, preferably in an aprotic solvent e.g. ether, THF or benzene; secondly, hydrolysis using an inorganic acid, preferably HCl in aqueous organic solvent at 0-100°C. Analogous routes are described in DE330945, EP31753, EP53964 and H. Sargent, *J. Am. Chem. Soc.* 68, 2688-2692 (1946).

15 In process variant (a)(iii) if a base is used it is preferably NaH, KH, an alkyl lithium e.g. BuLi, a metal alkoxide e.g. NaOEt, sodamide or lithium dialkylamide e.g. diisopropylamide. An analogous method is described in US 3989691 and in Taylor et al. (1972) *JACS* 94, 6218)

20 In process variant (a)(iv) the reaction is carried out in the presence of a base, preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt, preferably in an aprotic solvent, preferably THF, ether or benzene at -78 to 25°C (analogous process in Gutswiller et al. (1978) *JACS* 100, 576).

25 In process variant (a)(v) the reaction is carried out in the presence of a base, preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt, preferably in an aprotic solvent, preferably THF, ether or benzene at -78 to 25°C. An analogous method is described in US 3772302.

In process variant (a)(vi) a similar Claisen methodology to that described for (a)(ii) is used, analogous to that described in Soszko et. al., *Pr.Kom.Mat. Przyr.Poznan.Tow.Przyj.Nauk.*, (1962), 10, 15.

30 In process variants (a)(vii) and (viii) if a base is used it is preferably NaH, KH, an alkyl lithium e.g. BuLi, a metal alkoxide e.g. NaOEt, sodamide or lithium dialkylamide e.g. diisopropylamide. An analogous method is described in US 3989691 and M.Gates et. al. (1970) *J. Amer.Chem.Soc.*, 92, 205, as well as Taylor et al. (1972) *JACS* 94, 6218.

35 In process variant (a)(ix) the reaction is carried out using palladium catalysis. The palladium catalyst is preferably palladium acetate in the presence of trialkyl or triaryl phosphine and a trialkylamine e.g. triphenyl phosphine and tributylamine. An analogous method is described in S. Adam et. al. (1994) *Tetrahedron*, 50, 3327.

In process variant (a)(x), or (b) where Y is COW, the reaction is a standard amide formation reaction:

1. Activation of a carboxylic acid (e.g., to an acid chloride, mixed anhydride, active ester, O-acyl-isourea or other species), and treatment with an amine (Ogliaruso, M. A.; Wolfe, J. F. in *The Chemistry of Functional Groups* (Ed. Patai, S.) *Suppl. B: The Chemistry of Acid Derivatives, Pt. 1* (John Wiley and Sons, 1979), pp 442-8; Beckwith, A. L. J. in *The Chemistry of Functional Groups* (Ed. Patai, S.) *Suppl. B: The Chemistry of Amides* (Ed. Zabricky, J.) (John Wiley and Sons, 1970), p 73 ff. The acid and amide are preferably reacted in the presence of an activating agent such as 1-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) or 1-hydroxybenzotriazole (HOBT),
2. Aminolysis of esters (Suzuki, K.; Nagasawa, T. in *Encyclopedia of Reagents for Organic Synthesis* (Ed. Paquette, L. A.) (John Wiley and Sons, 1995), p 5188 and refs. cited therein.)
3. The specific methods of:
 - a. *in situ* conversion of an acid into the amine component by a modified Curtius reaction procedure (Shioiri, T.; Murata, M.; Hamada, Y., *Chem. Pharm. Bull.* **1987**, *35*, 2698)
 - b. *in situ* conversion of the acid component into the acid chloride under neutral conditions (Villeneuve, G. B.; Chan, T. H., *Tet. Lett.* **1997**, *38*, 6489).

In process variant (b) a final reduction step provides the required amine.

- In process variant (a)(xi) where one of X and Y contains NHR^{11} the leaving group V is halogen and the reaction is a standard amine formation reaction such as direct alkylation described in (Malpass, J. R., in *Comprehensive Organic Chemistry*, Vol. 2 (Ed. Sutherland, I. O.), p 4 ff.) or aromatic nucleophilic displacement reactions (see references cited in *Comprehensive Organic Chemistry*, Vol. 6, p 946-947 (reaction index); Smith, D. M. in *Comprehensive Organic Chemistry*, Vol. 4 (Ed. Sammes, P. G.) p 20 ff.). This is analogous to the methods described in GB 1177849.

- In process variant (a)(xi) where one of X and Y contains OH or SH, this is preferably converted to an OM or SM group where M is an alkali metal by treatment of an alcohol, thiol or thioacetate with a base. The base is preferably inorganic such as NaH, lithium diisopropylamide or sodium, or, for SH, metal alkoxide such as sodium methoxide. The X/Y group containing the thioacetate SCOR^X is prepared by treatment of an alcohol or alkyl halide with thioacetic acid or a salt thereof under Mitsunobu conditions. The leaving group V is a halogen. The reaction may be carried out as described in Chapman et.al., *J. Chem Soc.*, (1956), 1563, Gilligan et. al., *J. Med. Chem.*, (1992), *35*, 4344, Aloup et. al., *J. Med. Chem.* (1987), *30*, 24, Gilman et al., *J.A.C.S.* (1949), *71*, 3667 and Clinton et al., *J.A.C.S.* (1948), *70*, 491, Barluenga et al., *J. Org.*

Chem. (1987) 52, 5190. Alternatively where X is OH and Y is CH₂V, V is a hydroxy group activated under Mitsunobu conditions (Fletcher et.al. J Chem Soc. (1995), 623).

In process variants (a)(xii) and (b) where Y is CHO the reaction is a standard reductive alkylation using, e.g., sodium triacetoxyborohydride (Gribble, G. W. in *Encyclopedia of Reagents for Organic Synthesis* (Ed. Paquette, L. A.) (John Wiley and Sons, 1995), p 4649).

In process variant (a)(xiii), or (b) where X is CH₂OH and Y is -CH=N₂, the reaction is as described in den Hertzog et. al., *recl.Trav. Chim. Pays-Bas*, (1950), 69, 700.

In process variant (a)(xiv) the reaction of the compounds of formulae (IV) and (V) is a standard urea or carbamate formation reaction conducted by methods well known to those skilled in the art (for example see March, J; *Advanced Organic Chemistry, Edition 3* (John Wiley and Sons, 1985)). The process is preferably carried out in a polar, non-nucleophilic solvent such as N,N-dimethylformamide.

In process variant (c) the rearrangement may be effected by treatment with an acid, preferably an organic acid such as acetic acid and the reaction temperature is 80-120°C. Alternatively the compound of formula (II) is quaternised by treatment with an alkylating agent and treated with base such as KOH to give, depending upon the stereochemistry of the OH and the nature of the quaternary salt and base, either the ketone of formula (III) or an epoxide which can be opened to the alcohol of formula (VII) by reduction (see EP0035821).

In process variant (d) the reaction is preferably carried out in an alcohol, preferably methanol under irradiation conditions which are known to generate singlet oxygen as described in M. Ihara et.al. (1988), *J.Chem Soc Perkin Trans. 1*, 1277.

Reduction of A or B CO to CHOH can be readily accomplished using reducing agents well known to those skilled in the art, e.g. sodium borohydride in aqueous ethanol or lithium aluminium hydride in ethereal solution.. This is analogous to methods described in EP 53964, US 384556 and J. Gutzwiller et. al. (1978) *J.Amer.Chem.Soc.*, 100, 576.

The carbonyl group A or B may be reduced to CH₂ by treatment with a reducing agent such as hydrazine in ethylene glycol at 130-160°C in the presence of potassium hydroxide.

Reaction of a carbonyl group A or B with an organometallic reagent yields a group where R⁶ or R⁸ is OH and R⁷ or R⁹ is alkyl.

A hydroxy group in A or B may be oxidised to a carbonyl group by oxidants well known to those skilled in the art, for example, manganese dioxide, pyridinium chlorochromate or pyridinium dichromate.

An A-B group COCH_2 may be converted to COCH-halogen , by treating the ketone or a derivative with a halogenating agent, reduced to CHOHCHCl and then converted to the epoxide which may in turn be reduced to CH_2CHOH .

5 Methods for conversion of CH=CH by reduction to CH_2CH_2 are well known to those skilled in the art, for example using hydrogenation over palladium on carbon as catalyst. Methods for conversion of CH=CH to give the A-B group as CHOHCH_2 or CH_2CHOH are well known to those skilled in the art for example by epoxidation and subsequent reduction by metal hydrides, hydration, hydroboration or oxymercuration.

10 A hydroxyalkyl group A-B CH_2CHOH or CHOHCH_2 may be dehydrated to give the group CH=CH by treatment with an acid anhydride such as acetic anhydride.

An amide group $\text{CONHR}^{11'}$ or $\text{NHR}^{11'}\text{CO}$ may be reduced to the amine using a reducing agent such as lithium aluminium hydride

15 A ketone group may be converted to an amide CONH via the oxime by a Beckmann rearrangement (Ogliaruso, M.A.; Wolfe, J. F., *ibid.* pp 450-451; Beckwith, A. L. J., *ibid.* pp 131 ff.)

A hydroxy group in A or B may be converted to azido by activation and displacement e.g. under Mitsunobu conditions using hydrazoic acid or by treatment with diphenylphosphorylazide and base, and the azido group in turn may be reduced to amino by hydrogenation.

20 A sulphur group A or B may be converted to the sulfoxide S(O)_x by oxidation with peracids or a wide range of oxidants known to those skilled in the art (see Advanced Organic Chemistry (*Ed. March, J.*) (John Wiley and Sons, 1985), p 1089 and refs. cited therein).

25 $\text{R}^1, \text{R}^2, \text{R}^3$ and R^4 are preferably $\text{R}^1, \text{R}^2, \text{R}^3$ and R^4 . R^1 is preferably methoxy. R^2 is preferably hydrogen. R^3 is preferably vinyl or contains a carboxylate ester group. R^4 is preferably H, R^4 or a protecting group.

30 Conversions of $\text{R}^1, \text{R}^2, \text{R}^3$ and R^4 and interconversions of $\text{R}^1, \text{R}^2, \text{R}^3$ and R^4 are conventional. In compounds which contain an optionally substituted hydroxy group, suitable conventional hydroxy protecting groups which may be removed without disrupting the remainder of the molecule include acyl and alkylsilyl groups.

35 For example R^1 methoxy is convertible to R^1 hydroxy by treatment with lithium and diphenylphosphine (general method described in Ireland et. al. (1973) J.Amer.Chem.Soc., 7829) or HBr. Alkylation of the hydroxy group with a suitable alkyl derivative bearing a leaving group such as halide and a protected amino, piperidyl, amidino or guanidino group or group convertible thereto, yields, after conversion/deprotection, $\text{R}^1 \text{C}_{1-6}\text{alkoxy}$ substituted by optionally N-substituted amino, piperidyl, guanidino or amidino.

Examples of Z^{1'}-Z^{5'} are CR^{1a'} where R^{1a'} is a group convertible to R^{1a}.

R^{3'} alkenyl is convertible to hydroxyalkyl by hydroboration using a suitable reagent such as 9-borabicyclo[3.3.1]nonane, epoxidation and reduction or oxymercuration.

5 R^{3'} 1,2-dihydroxy can be prepared from R^{3'} alkenyl using osmium tetroxide or other reagents well known to those skilled in the art (see *Advanced Organic Chemistry (Ed. March, J.)* (John Wiley and Sons, 1985), p 732-737 and refs. cited therein) or epoxidation followed by hydrolysis (see *Advanced Organic Chemistry (Ed. March, J.)* (John Wiley and Sons, 1985), p 332,333 and refs. cited therein).

10 Opening an epoxide R^{3'} group with cyanide anion yields a CH(OH)-CH₂CN group.

Opening an epoxide-containing R^{3'} group with azide anion yields an azide derivative which can be reduced to the amine. Conversion of the amine to a carbamate is followed by ring closure with base to give the 2-oxo-oxazolidinyl containing R³ group.

15 Substituted 2-oxo-oxazolidinyl containing R³ groups may be prepared from the corresponding aldehyde by conventional reaction with a glycine anion equivalent, followed by cyclisation of the resulting amino alcohol (M Grauert et al, *Ann Chem* (1985) 1817, Rozenberg et al, *Angew Chem Int Ed Engl* (1994) 33(1) 91). The resulting 2-oxo-oxazolidinyl group contains a carboxy group which can be converted to other R¹⁰ groups
20 by standard procedures.

Carboxy groups within R³ may be prepared by Jones' oxidation of the corresponding alcohols CH₂OH using chromium acid and sulphuric acid in water/methanol (E.R.H. Jones et al, *J.C.S.* 1946,39). Other oxidising agents may be used for this transformation such as sodium periodate catalysed by ruthenium trichloride
25 (G.F.Tutwiler *et al*, *J.Med.Chem.*, 1987, 30(6), 1094), chromium trioxide-pyridine (G. Just *et al*, *Synth. Commun.* 1979, 9(7), 613), potassium permanganate (D.E.Reedich *et al*, *J. Org. Chem.*, 1985, 50(19), 3535, and pyridinium chlorochromate (D. Askin *et al*, *Tetrahedron Letters*, 1988, 29(3), 277).

The carboxy group may alternatively be formed in a two stage process, with an
30 initial oxidation of the alcohol to the corresponding aldehyde using for instance dimethyl sulphoxide activated with oxalyl chloride (N.Cohen *et al*, *J. Am. Chem. Soc.*, 1983, 105, 3661) or dicyclohexylcarbodiimide (R.M.Wengler, *Angew. Chim. Int. Ed. Eng.*, 1985, 24(2), 77), or oxidation with tetrapropylammonium perruthenate (Ley *et al*, *J. Chem.Soc. Chem Commun.*, 1987, 1625). The aldehyde may then be separately oxidised to the
35 corresponding acid using oxidising agents such as silver (II) oxide (R.Grigg *et al*, *J. Chem. Soc. Perkin1*, 1983, 1929), potassium permanganate (A.Zurcher, *Helv. Chim. Acta.*, 1987, 70 (7), 1937), sodium periodate catalysed by ruthenium trichloride (T.Sakata

et al, Bull. Chem. Soc. Jpn., 1988, 61(6), 2025), pyridinium chlorochromate (R.S.Reddy *et al*, Synth. Commun., 1988, 18(51), 545) or chromium trioxide (R.M.Coates *et al*, J. Am. Chem. Soc., 1982, 104, 2198).

- 5 An R^3 CO_2H group may also be prepared from oxidative cleavage of the corresponding diol, $CH(OH)CH_2OH$, using sodium periodate catalysed by ruthenium trichloride with an acetonitrile-carbon tetrachloride-water solvent system (V.S.Martin *et al*, Tetrahedron Letters, 1988, 29(22), 2701).

- 10 R^3 groups containing a cyano or carboxy group may also be prepared by conversion of an alcohol to a suitable leaving group such as the corresponding tosylate by reaction with para-toluenesulphonyl chloride (M.R.Bell, J. Med. Chem., 1970, 13, 389), or the iodide using triphenylphosphine, iodine, and imidazole (G. Lange, Synth. Commun., 1990, 20, 1473). The second stage is the displacement of the leaving group with cyanide anion (L.A.Paquette *et al*, J. Org. Chem., 1979, 44 (25), 4603; P.A.Grieco *et al*, J. Org. Chem., 1988, 53 (16), 3658). Finally acidic hydrolysis of the nitrile group gives the
15 desired acids (H.Rosemeyer *et al*, Heterocycles, 1985, 23 (10), 2669). The hydrolysis may also be carried out with base e.g. potassium hydroxide (H.Rapoport, J. Org. Chem., 1958, 23, 248) or enzymatically (T. Beard *et al*, Tetrahedron Asymmetry, 1993, 4 (6), 1085).

Other functional groups in R^3 may be obtained by conventional conversions of carboxy or cyano groups.

- 20 Tetrazoles are conveniently prepared by reaction of sodium azide with the cyano group (e.g. F. Thomas *et al*, Bioorg. Med. Chem. Lett., 1996, 6 (6), 631; K.Kubo *et al*, J. Med. Chem., 1993, 36, 2182) or by reaction of azidotri-n-butyl stannane with the cyano group followed by acidic hydrolysis (P.L.Omstein, J. Org. Chem., 1994, 59, 7682 and J. Med. Chem., 1996, 39 (11), 2219).

- 25 The 3-hydroxy-3-cyclobutene-1,2-dione-4-yl group (e.g. R.M.Soll, Bioorg. Med. Chem. Lett., 1993, 3 (4), 757 and W. A. Kinney, J. Med. Chem., 1992, 35 (25), 4720) can be prepared by the following sequence:- (1) a compound where R^3 is $(CH_2)_nCHO$ ($n = 0, 1, 2$) is treated with triethylamine, carbon tetrabromide triphenylphosphine to give initially $(CH_2)_nCH=CHBr$; (2) dehydrobromination of this intermediate to give the
30 corresponding bromoethyne derivative $(CH_2)_nC\equiv CBr$ (for this 2 stage sequence see D. Grandjean *et al*, Tetrahedron Letters, 1994, 35 (21), 3529); (3) palladium-catalysed coupling of the bromoethyne with 4-(1-methylethoxy)-3-(tri-n-butylstannyl)cyclobut-3-ene-1,2-dione (Liebeskind *et al*, J. Org. Chem., 1990, 55, 5359); (4) reduction of the ethyne moiety to $-CH_2CH_2-$ under standard conditions of hydrogen and palladium on charcoal catalysis (see Howard *et al*, Tetrahedron, 1980, 36, 171); and finally (4) acidic
35 hydrolysis of the methylethoxyester to generate the corresponding 3-hydroxy-3-cyclobutene-1,2-dione group R.M.Soll, Bioorg. Med. Chem. Lett., 1993, 3 (4), 757).

The tetrazol-5-ylaminocarbonyl group may be prepared from the corresponding carboxylic acid and 2-aminotetrazole by dehydration with standard peptide coupling agents such as 1,1'-carbonyldiimidazole (P. L. Ornstein et al, J. Med Chem, 1996, 39 (11), 2232).

- 5 The alkyl- and alkenyl-sulphonylcarboxamides are similarly prepared from the corresponding carboxylic acid and the alkyl- or alkenyl-sulphonamide by dehydration with standard peptide coupling agents such as 1,1'-carbonyldiimidazole (P. L. Ornstein et al, J. Med. Chem., 1996, 39 (11), 2232).

- 10 The hydroxamic acid groups are prepared from the corresponding acids by standard amide coupling reactions eg N. R. Patel et al, Tetrahedron, 1987, 43 (22), 5375

2,4-Thiazolidinedione groups may be prepared from the aldehydes by condensation with 2,4-thiazolidinedione and subsequent removal of the olefinic double bond by hydrogenation.

- 15 The preparation of 5-oxo-1,2,4-oxadiazoles from nitriles is described by Y. Kohara et al, Bioorg. Med. Chem. Lett., 1995, 5(17), 1903.

- 1,2,4-Triazol-5-yl groups may be prepared from the corresponding nitrile by reaction with an alcohol under acid conditions followed by reaction with hydrazine and then an R¹⁰-substituted activated carboxylic acid (see JB Polya in 'Comprehensive Heterocyclic Chemistry' Edition 1 p762, Ed AR Katritzky and CW Rees, Pergamon Press, 20 Oxford 1984 and J.J. Ares et al, J. Heterocyclic Chem., 1991, 28(5), 1197).


- Other substituents on R³ alkyl or alkenyl may be interconverted by conventional methods, for example hydroxy may be derivatised by esterification, acylation or etherification. Hydroxy groups may be converted to halogen, thiol, alkylthio, azido, alkylcarbonyl, amino, aminocarbonyl, oxo, alkylsulphonyl, alkenylsulphonyl or 25 aminosulphonyl by conversion to a leaving group and substitution by the required group or oxidation as appropriate or reaction with an activated acid, isocyanate or alkoxyisocyanate. Primary and secondary hydroxy groups can be oxidised to an aldehyde or ketone respectively and alkylated with a suitable agent such as an organometallic reagent to give a secondary or tertiary alcohol as appropriate.

- 30 NH is converted to NR⁴ by conventional means such as alkylation with an alkyl halide in the presence of base, acylation/reduction or reductive alkylation with an aldehyde.

- It will be appreciated that under certain circumstances interconversions may interfere, for example, A or B hydroxy groups and the piperidine NH will require 35 protection e.g. as a carboxy- or silyl-ester group for hydroxy and as an acyl derivative for piperidine nitrogen, during conversion of R^{1'}, R^{2'}, R^{3'} or R^{4'}, or during the coupling of the compounds of formulae (IV) and (V).

Examples containing a *trans*-3,4-substituted piperidine ring may be prepared from the *trans*-3-vinyl-4-substituted piperidine prepared from the corresponding 3-vinyl-4-*cis*-isomer by the method of G. Engler *et al.* *Helv. Chim. Acta* 68, 789-800 (1985); also described in Patent Application EP 0031753 (Pharmindustrie).

- 5 The method involves heating a 3-vinyl-4-alkyl-piperidine derivative of formula (VIII):



- 10 (prepared as an intermediate in the process of the invention) in dilute acid, preferably hydrochloric acid at pH 3.5, with 0.3-1.0 mol equivalents of formaldehyde. The main product of the reaction is the *trans*-isomer, which may be separated from the small quantity of *cis* isomer present, by conventional silica gel chromatography. It is convenient to convert the mixture of *cis*- and *trans*-piperidines ($R^{4'} = H$) to the tertiary amines of formula (I) by alkylation with an alkyl halide (preferably an iodide) in DMF in
- 15 the presence of anhydrous potassium carbonate, prior to silica gel chromatography.

Compounds of formula (II) include quinine and derivatives thereof.

Compounds of formula (VI) are known compounds or may be prepared analogously, see for example Ihara *et al* *JCS Perkin 1* 1988, 1277-1281.

- 20 Compounds of formulae (IV), (V) and (Vb) are known compounds, (see for example Smith *et al*, *J. Amer. Chem. Soc.*, 1946, 68, 1301) or prepared analogously, see for example the references cited above for reaction variant (a).

- 25 An isocyanate of formula (IV) may be prepared conventionally. A 4-amino derivative such as 4-amino-quinoline, and phosgene, or phosgene equivalent (eg triphosgene) provide the isocyanate or it may be prepared more conveniently from a 4-carboxylic acid by a 'one-pot' Curtius Reaction with diphenyl phosphoryl azide (DPPA) [see T. Shiori *et al.* *Chem. Pharm. Bull.* 35, 2698-2704 (1987)].

- 30 The 4-carboxy derivatives are commercially available or may be prepared by conventional procedures for preparation of carboxy heteroaromatics well known to those skilled in the art. For example, quinazolines may be prepared by standard routes as described by T.A. Williamson in *Heterocyclic Compounds*, 6, 324 (1957) Ed. R.C. Elderfield. Pyridazines may be prepared by routes analogous to those described in *Comprehensive Heterocyclic Chemistry*, Volume 3, Ed A.J. Boulton and A. McKillop

and naphthyridines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 2, Ed A.J. Boulton and A. McKillop.

The 4-amino derivatives are commercially available or may be prepared by conventional procedures from a corresponding 4-chloro derivative by treatment with ammonia (O.G. Backeberg et. al., J. Chem Soc., 381, 1942.) or propylamine hydrochloride (R. Radinov et. al., Synthesis, 886, 1986).

A 4-chloroquinoline is prepared from the corresponding quinolin-4-one by reaction with phosphorus oxychloride (POCl_3) or phosphorus pentachloride, PCl_5 . A 4-chloroquinazoline is prepared from the corresponding quinazolin-4-one by reaction with phosphorus oxychloride (POCl_3) or phosphorus pentachloride, PCl_5 . A quinazolinone and quinazolines may be prepared by standard routes as described by T.A. Williamson in Heterocyclic Compounds, 6, 324 (1957) Ed. R.C. Elderfield. Pyridazines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 3, Ed A.J. Boulton and A. McKillop and naphthyridines may be prepared by routes analogous to those described in Comprehensive Heterocyclic Chemistry, Volume 2, Ed A.J. Boulton and A. McKillop.

4-Hydroxy-1,5-naphthyridines can be prepared from 3-aminopyridine derivatives by reaction with diethyl ethoxymethylene malonate to produce the 4-hydroxy-3-carboxylic acid ester derivative with subsequent hydrolysis to the acid, followed by thermal decarboxylation in quinoline (as for example described for 4-Hydroxy-[1,5]naphthyridine-3-carboxylic acid, Joe T. Adams et al., J. Amer. Chem. Soc., 1946, 68, 1317). A 4-hydroxy-[1,5]naphthyridine can be converted to the 4-chloro derivative by heating in phosphorus oxychloride. A 4-amino 1,5-naphthyridine can be obtained from the 4-chloro derivative by reaction with n-propylamine in pyridine. Similarly, 6-methoxy-1,5-naphthyridine derivatives can be prepared from 3-amino-6-methoxypyridine.

4-Methyl-1,5-naphthyridines can be prepared by methods well known to those skilled in the art (for example see H. Rapoport and A. D. Batcho, Journal of Organic Chemistry, 1963, 1753-1759). For example, nitrobenzene can be heated with oleum over a period of hours then water and a 3-aminopyridine added with heating. Slow addition of methyl vinyl ketone with heating produces the desired 4-methyl-1,5-naphthyridine.

1,5-Naphthyridines may be prepared by other methods well known to those skilled in the art (for examples see P.A. Lowe in "Comprehensive Heterocyclic Chemistry" Volume 2, p581-627, Ed A.R. Katritzky and C.W. Rees, Pergamon Press, Oxford, 1984).

The 4-hydroxy and 4-amino-cinnolines may be prepared following methods well known to those skilled in the art [see A.R. Osborn and K. Schofield, J. Chem. Soc. 2100 (1955)]. For example, a 2-aminoacetophenone is diazotised with sodium nitrite and acid to produce the 4-hydroxycinnoline with conversion to chloro and amino derivatives as described for 1,5-

naphthyridines. A 3-methyl substituent may be introduced by reaction of a 4-chlorocinnoline with lithium diisopropylamide at -75°C followed by alkylation with methyl iodide [see A. Turck et al. *Tetrahedron*, **47**, 13045 (1995)].

For compounds of formula (V) where Y is $\text{NHR}^{11'}$ suitable amines may be prepared from the corresponding acid or alcohol (Y is CO_2H or CH_2OH). In a first instance, an N-protected piperidine containing an acid bearing substituent, can undergo a Curtius rearrangement and the intermediate isocyanate can be converted to a carbamate by reaction with an alcohol. Conversion to the amine may be achieved by standard methods well known to those skilled in the art used for amine protecting group removal. For example, an acid substituted N-protected piperidine can undergo a Curtius rearrangement e.g. on treatment with diphenylphosphoryl azide and heating, and the intermediate isocyanate reacts in the presence of 2-trimethylsilylethanol to give the trimethylsilylethylcarbamate (T.L.Capson & C.D.Poulter, *Tetrahedron Letters*, 1984, **25**, 3515). This undergoes cleavage on treatment with tetrabutylammonium fluoride to give the 4-amine substituted N-protected piperidine. Alternatively, an acid group $(\text{CH}_2)_{n-1}\text{CO}_2\text{H}$ may be converted to $(\text{CH}_2)_n\text{NHR}^{11'}$ by reaction with an activating agent such as isobutyl chloroformate followed by an amine $\text{R}^{11'}\text{NH}_2$ and the resulting amide reduced with a reducing agent such as LiAlH_4 .

In a second instance, an N-protected piperidine containing an alcohol bearing substituent undergoes a Mitsunobu reaction (for example as reviewed in Mitsunobu, *Synthesis*, (1981), 1), for example with succinimide in the presence of diethyl azodicarboxylate and triphenylphosphine to give the phthalimidoethylpiperidine. Removal of the phthaloyl group, for example by treatment with methylhydrazine, gives the amine of formula (V).

Conversions of $\text{R}^{1'}$, $\text{R}^{2'}$, $\text{R}^{3'}$ and $\text{R}^{4'}$ may be carried out on the intermediates of formulae (II), (IV), (V), (Vb) and (VI) prior to their reaction to produce compounds of formula (I) in the same way as described above for conversions after their reaction.

Where a *trans*-substituted compound of formula (I) is required, a *trans*-substituted piperidine moiety of formula (V) may be prepared from the corresponding *cis* isomer of formula (V) having an $\text{R}^{3'}$ vinyl group in the 3-position with a substituent that can subsequently be converted to the required group $(\text{CH}_2)_n\text{Y}$, for example $\text{CH}_2\text{CO}_2\text{R}$ (where R is an alkyl group eg methyl or ethyl), by heating in formaldehyde.

The pharmaceutical compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.

The antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics.

The composition may be formulated for administration by any route, such as oral, topical or parenteral. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

5 The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.

10 The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.

15 Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical
20 practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl
25 cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.

30 Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.

35 For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.

Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.

No toxicological effects are indicated when a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof is administered in the above-mentioned dosage range.

The compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a β -lactamase inhibitor may be employed.

Compounds of formula (I) are active against a wide range of organisms including both Gram-negative and Gram-positive organisms.

The following examples illustrate the preparation of certain compounds of formula (I) and the activity of certain compounds of formula (I) against various bacterial organisms.

EXAMPLES**Example 1 [3R, 4R]-1-Heptyl-3-(1-(R or S)-hydroxy-2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine**

a) [3R,4R]-3-Ethenyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine.

5 A solution of quinine (497g) in acetic acid (460 ml) and water (3.8 l) was heated to reflux for 2 days. The mixture was basified with 40% aqueous sodium hydroxide solution and extracted (2x) with dichloromethane. The organic extracts were washed with brine, dried (Na₂SO₄) and evaporated affording the title compound as a brown oil (497g, 100%).

10 EI MH⁺ 325, C₂₀H₂₄N₂O requires 324.

b) [3R,4R]-3-Ethenyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine.

A solution of Example 1a (231.5g, 0.71 mol) in ethylene glycol (1.0l) was treated with hydrazine hydrate (50g, 1.0 mol) over 0.3 h. The mixture was warmed to 120°C for
15 1.5h. The mixture was then cooled to 10°C and potassium hydroxide (92.7g) was added and the mixture extracted with dichloromethane (2x). The dichloromethane extracts were washed with brine, dried (Na₂SO₄), and evaporated affording the title compound as a brown oil (217g, 100%).

EI MH⁺ 311 C₂₀H₂₆N₂O requires 310.

20

c) [3R,4R]-1-Benzoyloxycarbonyl-3-ethenyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine.

A solution of crude Example 1b (496g, 1.5mol) in tetrahydrofuran (4.5 l) and water 3.3 l) was treated with solid potassium carbonate (219.6g, 1.6mol) and then a
25 solution of benzyl chloroformate (258g, 1.5mol) in tetrahydrofuran (0.4 l) was added over 1 h. The mixture was stirred at room temperature for 15 h then sodium chloride (500g) and ethyl acetate (2.5 l) were added. After stirring for 0.25 h the organic phase was separated and the aqueous phase re-extracted with ethyl acetate. The combined ethyl acetate extracts were dried (Na₂SO₄) and evaporated affording as brown oil. This was
30 chromatographed (in two portions) on 2.5kg silica Biotage cartridges eluting first with dichloromethane then 5% ethyl acetate in hexane to give the title compound a clear oil that crystallised on standing (450.5g, 67%).

EI MH⁺ 445 C₂₈H₃₂N₂O₃ requires 444.

35 d) [3R,4R]-1-Benzoyloxycarbonyl-3-(1-(R,S)-2-dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine

A solution of Example 1c (215g, 0.48mol) in acetone (4.2 l) and water 0.53 l) under argon at 0°C was treated with osmium tetroxide (2.5g) in *t*-butanol (300 ml) dropwise over 0.5 h. A solution of N-methylmorpholine-N-oxide (77.6g, 0.66 mol) was in water (0.7 l) was then added dropwise over 1 h. The mixture was stirred for 16 h at
5 room temperature. A solution of sodium metabisulphite (65.5g, 0.34 mol) in water (0.5 l) was added. After 4 h the mixture was filtered through celite (CAUTION – to remove Osmium metal), washing with acetone. The filtrate was concentrated by evaporation then solid sodium bicarbonate (50g) and ethyl acetate (2.5 l) were added. The organic extract was washed with brine dried (Na₂SO₄), and evaporated, giving a yellow oil (235g). This
10 was purified by chromatography on a 2.5kg silica biopage cartridge eluting with 1:1 ethyl acetate:hexane, neat ethyl acetate, then up to 5% methanol in ethyl acetate, affording the title compound as a yellow oil (179.9g, 78%).
EI MH⁺ 478 C₂₈H₃₄N₂O₅ requires 477.

15 e) [3R, 4R]-1-Benzylloxycarbonyl-3-(2-(R, S)-oxiranyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

This was prepared by a modification of a related procedure by S. Takano *et al.*, Synthesis, 1983, 116.

The above diol Example 1d (9.0g, 18.8 mmol) was dissolved in toluene (150ml)
20 then triphenylphosphine (7.4g, 28.2 mmol) and diethylazodicarboxylate (4.9g, 28.2 mmol) were added. The mixture was heated to reflux under argon for 2.5 days. Evaporation and chromatography on silica eluting with a gradient of ethyl acetate/hexane (70/30) to neat ethyl acetate afforded a white solid (20.0g). Analysis of this material showed it to contain ca. 9g of the title compound, the balance being triphenylphosphine
25 oxide.

E.I MH⁺ 461 C₂₈H₃₂N₂O₄ requires 460

f) [3R, 4R]-1-Benzylloxycarbonyl-3-(1-(R,S)-hydroxy-2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

30 The above semi-purified epoxide Example 1e (10.9g, equivalent to approximately 5.0g, 10.9 mmol) was dissolved in tetrahydrofuran (160 ml) and treated with lithium cyanide in N,N-dimethylformamide (0.5 M; 100ml, 50mmol). The mixture was heated to reflux under argon for 9 hours, and evaporated to dryness. The residue was partitioned between ethyl acetate and water. The organic extract was dried and evaporated affording
35 the crude product as a brown solid (11g).

E.I. MH⁺ 488, C₂₉H₃₃N₃O₄ requires 487.

g) [3R, 4R]-3-(1-(R, S)-hydroxy-2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

The above crude cyanohydrin Example 1f (approximately 10.9 mmol) was dissolved in ethanol (130ml) and hydrogenated over 10% palladium on charcoal (5.6g) for 21 hours. Filtration and evaporation afforded a brown oil. Chromatography on silica eluting with a mixture of aqueous ammonia:methanol:dichloromethane (1.5:15:30) afforded the pure product as an inseparable 2:1 mixture of diastereomers as a clear oil (1.28g, 33% over two stages from epoxide 1e)

E.I. MH^+ 354, $C_{21}H_{27}N_3O_2$ requires 353.

h) Title compounds

The above piperidine Example 1g (1.26g, 3.6 mmol) was dissolved in N,N-dimethylformamide (20ml), then treated with potassium carbonate (0.6g, 4.3 mmol) and heptyl iodide (0.65 ml, 0.9g, 3.9mmol). After 3.5 h the reaction mixture was evaporated and the residue partitioned between ethyl acetate and dilute brine. The organic extract was dried and evaporated giving a brown oil. Chromatography on silica eluting with aqueous ammonia-ethanol-dichloromethane (1.5-15-350) affording the individual diastereomers as yellow oil (combined yield 0.56g, 34%).

E.I. MH^+ 452, $C_{28}H_{41}N_3O_2$ requires 451.

Example 2. [3R, 4R]-1-Heptyl-3-(2-(R or S)-oxo-oxazolidin-5-yl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine

a) [3R, 4R]-1-Benzyloxycarbonyl-3-(1-(R,S)-hydroxy-2-azidoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

This was prepared by the same procedure as for Example 1f, except that sodium azide was used instead of lithium cyanide and 0.5 equivalents of ammonium chloride were included in the reaction mixture.

E.I. MH^+ 504, $C_{28}H_{33}N_5O_4$ requires 503.

b) [3R, 4R]-1-Benzyloxycarbonyl-3-(1-(R,S)-hydroxy-2-aminoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

The crude product Example 2a (2.58g, contaminated with $Ph_3P=O$) was dissolved in ethanol (70ml) and hydrogenated over 10% palladium on charcoal (0.9g) for 0.5h. This facilitated the selective reduction of the azide functionality in the presence of the N-benzyloxycarbonyl protecting group. Filtration and evaporation afforded the crude product as a pale yellow solid (2.3g).

E.I. MH^+ 478, $C_{28}H_{35}N_3O_4$ requires 477.

c) [3R, 4R]-1-Benzoyloxycarbonyl-3-(1-(R,S)-hydroxy-2-benzoyloxycarbonylaminoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine

The above crude product (Example 2b) was dissolved in ethyl acetate and vigorously stirred with an equal volume of saturated aqueous sodium bicarbonate solution. Benzyl chloroformate (1.3 equivalents) was added and the mixture stirred under argon for 5 h. The phases were separated and the ethyl acetate extract dried and evaporated. The crude material was purified by chromatography eluting with an ethyl acetate/hexane gradient.

E.I. MH⁺ 612, C₃₆H₄₁N₃O₆ requires 611

d) [3R, 4R]-1-Benzoyloxycarbonyl-3-(2-(R,S)-oxo-oxazolidin-5-yl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

The above alcohol (0.16g, 0.26mmol) was dissolved in a mixture of water:methanol:tetrahydrofuran (0.75ml:1.5ml:3ml) containing potassium hydroxide (0.32g). The mixture was stirred for 3h at room temperature then diluted with water (10ml) and extracted with ethyl acetate (30ml). The organic extract was dried (Na₂ SO₄) and evaporated. The crude material was purified by chromatography on silica eluting with a 0→2% ethanol in ethyl acetate gradient affording the product as a yellow oil (0.1g, 80%).

E.I. MH⁺ 504, C₂₉H₃₃N₃O₅ requires 503.

e) [3R, 4R]-3-(2-(R,S)-oxo-oxazolidin-5-yl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine

Hydrogenation of the above compounds (Example 1d) according to the method for Example 1g with the variation that the reaction time was 4 h, gave the title compounds as an oil.

E.I. MH⁺ 370, C₂₁H₂₇N₃O₃ requires 369

f) Title compound

The title compounds were prepared by N-heptylation of the above compound (Example 2e) according to the method of Example 1h followed by chromatography on silica eluting with aqueous ammonia:ethanol:chloroform (1.5:15:400) to give the individual diastereomers (65mg and 24mg) as oils in a combined yield of 34%.

E.I. MH⁺ 468, C₂₈H₄₁N₃O₃ requires 467.

Example 3. [3R, 4R]-1-Heptyl-3-(2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl] piperidine.

a) [3R,4R]-1-Benzoyloxycarbonyl-3-(2-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine.

- 5 The olefin Example 1c (10.00 g, 22.5 mmol) was dissolved in tetrahydrofuran (300 ml) and treated with a solution of 9-borabicyclo(3.3.1)nonane in hexane (0.5M, 135 ml, 67.6 mmol) and heated to reflux for 24h under argon. The cooled reaction mixture was treated with ethanol (70 ml) and 2M aqueous sodium hydroxide solution (70 ml), then 27.5 w/v aqueous hydrogen peroxide solution (45 ml) was added over 20
10 minutes. After 1h ethyl acetate and water were added, and the organic extract dried and evaporated. The crude product was purified by chromatography on silica gel eluting with an ethyl acetate gradient affording the title product as a yellow oil (6.3g, 60%).
E.I. MH^+ 463, $C_{28}H_{34}N_2O_4$ requires 462.

- 15 b) (3R, 4R)-3-(2-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl] piperidine.

This was prepared in approximately quantitative yield from the above N-benzoyloxycarbonyl piperidine (Example 3a) by hydrogenation according to the procedure for Example 1g, with the variation that the reaction time was 3h.

E.I. MH^+ 329, $C_{20}H_{28}N_2O_2$ requires 328.

20

- c) (3R, 4R)-1-*t*-butyloxycarbonyl-3-(2-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl] piperidine.

- Example 3b was dissolved in dichloromethane-N,N-dimethylformamide and treated with triethylamine (1.2 eq), di-*t*-butylcarbonic anhydride (1.1 equivalents) and
25 N,N-dimethylaminopyridine (catalytic quantity). After stirring overnight the mixture was evaporated and purified by chromatography on silica eluting with a gradient of ethyl acetate/hexane, giving the product as an oil (3.8g, 34%)

E.I. MH^+ 429, 329 (loss of $CO_2C_4H_9$), $C_{25}H_{36}N_2O_4$ requires 428.

- 30 d) (3R, 4R)-1-*tert*-butyloxycarbonyl-3-[2-(4-methylphenyl)sulfonyloxyethyl]-4-[3-(6-methoxyquinolin-4-yl)propyl] piperidine.

- Example 3c (2.2g, 5.1 mmol) was dissolved in dichloromethane (50ml), then triethylamine (0.85ml, 0.62g, 6.1 mmol), N,N-dimethylaminopyridine (catalytic) and 4-methylphenylsulfonyl chloride (1.1g, 5.6 mmol)
35 were added. After 20h the mixture was diluted with more dichloromethane and washed with water. The organic extract was dried (Na_2SO_4) and evaporated.

Chromatography on silica eluting with ethyl acetate:hexane (1:1) afforded the product as a yellow oil (1.8g, 61%).

E.I. MH+ 583, C₃₂H₄₂N₂O₆S requires 582.

- 5 e) (3R, 4R)-1- *t*-butoxycarbonyl-3-(2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

Example 3d (1.8g, 31mmol) was dissolved in N,N-dimethylformamide (15ml) and treated with sodium cyanide (0.3g, 6.2 mmol). The mixture was stirred at room temperature for 16 h then at 40° for 1h. The mixture was evaporated to dryness and the residue was partitioned between ethyl acetate and water. The organic extract was dried (MgSO₄) and evaporated to give the product as an oil, (67%).

E.I. MH+ 438, C₂₆H₃₅N₃O₃ requires 437.

- 15 f) (3R, 4R)-3-(2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.
Example 3e (0.9g) was treated with 1:1 trifluoroacetic acid:dichloromethane (25 ml) at 0 C. After 1h the reaction mixture was evaporated and the residue partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution.. The organic extract was dried and evaporated to give the title compound as an oil in approximately quantitative yield.

20 E.I. MH+ 338, C₂₁H₂₇N₂O₂ requires 337.

- g) Title compound

The title compound was prepared from Example 3f by heptylation using the procedure of Example 1h, giving the purified product as an oil

25 (0.55g, 62%)

E.I. MH+ 436, C₂₈H₁₄N₃O requires 435.

Example 4. [3R, 4R]-1-Heptyl-3-(3-carboxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

- 30 Hydrolysis of the corresponding cyanoethyl compound (Example 3g) (0.35g, 0.8mmol) with concentrated hydrochloric acid and dioxane (9ml of each) at reflux for 11h followed by evaporation and chromatography on silica (eluting with 1.5:15:50 aqueous ammonia:methanol:chloroform) afforded the title compound (0.23g, 55%) as an oil.

35 E.I. MH+, 455, C₂₈H₄₂N₂O₂ requires 454.

Example 5. [3R, 4R]-1-Heptyl-3-carboxy-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

a) (3R, 4R)-3-(1-(R,S)-2-Dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine

- 5 The title compounds (4.7g) were prepared in approximately quantitative yield by hydrogenation of Example 1d according to the same procedure as for Example 1g, with the variation the reaction time was 3h.

E.I. MH⁺ 345, C₂₀H₂₈N₂O₃ requires 344.

- 10 b) (3R, 4R)-3-(1-(R,S)-2-Dihydroxyethyl)-1-heptyl-4-[3-(6-methoxyquinolin-4-yl) propyl]piperidine

- The title compounds were prepared in approximately 60% yield by alkylation at room temperature with heptyl iodide (1.1 equivalents) in N,N-dimethylformamide as solvent and potassium carbonate (1.2 equivalents) as base, following an analogous
15 procedure to Example 1h.

E.I. MH⁺ 443, C₂₇H₄₂N₂O₃ requires 442.

c) Title compounds

- A solution of the above diol (Example 5b) (0.4g) in acetone (10ml) was treated at
20 0°C with Jones reagent (~50 drops). After 2h the reaction mixture was neutralised with saturated aqueous sodium bicarbonate solution and extracted (3x) with ethyl acetate. The combined organic extracts were dried and evaporated. Chromatography on silica eluting with aqueous ammonia-ethanol-chloroform (1.5:15:300) afforded the title compounds as a yellow oil (32 mg, 8%).

- 25 E.I. MH⁺ 427, C₂₆H₃₈N₂O₃ requires 426.

Example 6. [3R, 4R]-1-Heptyl-3-(carboxymethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine.

a) [3R,4R]-3-Ethenyl-1-heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine

- 30 This was prepared in 66% yield from (Example 1b) by heptylation according to the procedure for Example 1h.

E.I. MH⁺ 409, C₂₇H₄₀N₂O requires 408.

- b) (3R, 4R)-1-heptyl-3-(2-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl]
35 piperidine

 This was prepared from Example 6a in 40% yield by the same hydroboration/oxidation procedure as for Example 3a.

E.I. MH+ 427, C₂₇H₄₂N₂O₂ requires 426.

c) (3R, 4R)-1-heptyl-3-(2-carboxymethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine

- 5 This was prepared in 15% yield from Example 6b using the same oxidation procedure as for Example 5c.

E.I. M⁺H 441, C₂₇H₄₀N₂O₃ requires 440.

10 **Example 7 [3R, 4R]-1-Heptyl-3-(1-(R or S)-hydroxy-2-carboxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine**

A solution of Example 1 (60 mg, 0.13 mmol) in concentrated hydrochloric acid:dioxane (6 ml:3 ml) was heated to reflux for 4h. The mixture was neutralised with saturated aqueous sodium bicarbonate solution and extracted (3X) with ethyl acetate. The combined organic extracts were dried and evaporated and the crude product
15 chromatographed on silica eluting with aqueous ammonia:methanol:chloroform (1.5:15:50) giving the title compounds as a colourless oil, (0.019g, 30%).

E.I. MH+ 471, C₂₈H₄₂N₂O₃ requires 470.

20 **Example 8 [3R, 4R]-1-Heptyl-3-(2-(E)-carboxyethenyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine**

A solution of Example 1 (48 mg, 0.11 mmol) in concentrated hydrochloric acid:dioxane (5 ml:3 ml) was heated to reflux for 24h. The mixture was neutralised with saturated aqueous sodium bicarbonate solution and extracted (3X) with ethyl acetate. The
25 combined organic extracts were dried and evaporated and the crude product chromatographed on silica eluting with aqueous ammonia:methano:chloroform (1.5:15:50) giving the title compound as a colourless oil, (0.015g, 31%).

E.I. MH+ 453, C₂₈H₄₀N₂O₂ requires 452.

30 **Example 9. N-(cis-3-(R/S)-Ethoxycarbonyl-1-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxyquinolin-4-yl)urea oxalate**

a) 4-Benzylamino-1-tert-butoxycarbonyl-3-ethoxycarbonyl-1,2,5,6-tetrahydropyridine

A solution of 1-tert-butoxycarbonyl-3-ethoxycarbonylpiperidin-4-one (prepared from 3-ethoxycarbonylpiperidin-4-one and di-tert-butyl-dicarbonate in dichloromethane and triethylamine) (25g) and benzylamine (10.85g) in toluene was heated under reflux in
35 a Dean and Stark apparatus for 18 hours and then evaporated to dryness to give an oil.

b) cis- 4-(S/R)-Benzylamino-1-tert-butoxycarbonyl-3-(R/S)-ethoxycarbonylpiperidine

The enamine (9a) (25g) in ethanol (300ml) was hydrogenated over platinum oxide (1.5g) for 4 days, filtered, and evaporated to dryness. It was chromatographed on silica gel (ethyl acetate-hexane) to afford the title compound as an oil.

5 MS (+ve ion electrospray) m/z 363 (MH+).

c) cis-4-(S/R)-Amino-1-tert-butoxycarbonyl-3-(R/S)-ethoxycarbonylpiperidine

The amine (9b) (4g) in ethanol (80ml) containing acetic acid (0.73g) was hydrogenated at 50psi (Parr reaction vessel) over 10% palladium-carbon (1g) for 18
10 hours, filtered and evaporated to dryness to afford the acetate salt of the title compound as a white solid (3g).

MS (+ve ion electrospray) m/z 273 (MH+).

It was converted to the oily free base by extraction using dichloromethane-sodium carbonate and drying over sodium sulfate.

15

d) N-(cis-1-tert-Butoxycarbonyl-3-(R/S)-ethoxycarbonyl-4-(S/R)-piperidyl)-N'-(6-methoxyquinolin-4-yl)urea

A suspension of 6-methoxyquinoline-4-carboxylic acid (0.98g) in dry toluene (50ml) was treated with triethylamine (1.95g) followed by diphenylphosphoryl azide
20 (1.39g) and the mixture was stirred at room temperature for 8 hours. The resultant solution was treated with the amine (9c) and then heated under reflux for 4 hours and evaporated to dryness. The product was chromatographed on silica gel (ethyl acetate-hexane) to afford the title compound (1.98g) as a foam.

MS (+ve ion electrospray) m/z 473 (MH+).

25

e) N-(cis-3-(R/S)-Ethoxycarbonyl-4-(S/R)-piperidyl)-N'-(6-methoxyquinolin-4-yl)urea

The urea (9d) (1.0g) was treated with dichloromethane (30ml) and trifluoroacetic acid (20ml) at room temperature for 3 hours and evaporated to dryness. It was basified with sodium carbonate solution and evaporated to dryness. The solid was extracted three
30 times with ethanol-chloroform (1:9) and evaporated to dryness to afford a foam (0.75g).

MS (+ve ion electrospray) m/z 373 (MH+).

f) Title compound

The amine (9e) (0.75g) in dry ethanol (15ml) was treated with heptaldehyde
35 (0.636g) and sodium triacetoxyborohydride (0.459g) for 1 hour at room temperature. Sodium bicarbonate solution was added and the mixture was extracted with dichloromethane, dried over sodium sulfate, and evaporated to afford an oil.

Chromatography on silica gel (ethyl acetate-hexane) gave the title compound (0.68g) as an oil.

MS (+ve ion electrospray) m/z 471 (MH⁺).

The free base in dichloromethane was treated with 1 molar equivalent of oxalic acid in ether and the resulting solid was collected, triturated with ether, to afford the oxalate salt as a white solid.

Example 10. N-(cis-3-(R/S)-Ethoxycarbonyl-1-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxy-[1,5]-naphthyridin-4-yl)urea oxalate

10 a) 4-Hydroxy-6-methoxy-[1,5]naphthyridine-3-carboxylic acid ethyl ester

3-Amino-6-methoxypyridine (12.41 g) and diethyl ethoxymethylene malonate (20.2 ml) in Dowtherm A (400 ml) were heated at reflux, under argon for 1 hour. The cooled reaction mixture was poured into pentane (1 litre). The precipitated solid was collected by filtration, washed with pentane and dried to afford a solid (24.78 g, crude).

15

b) 4-Hydroxy-6-methoxy-[1,5]naphthyridine-3-carboxylic acid

The ester (10a) (0.642g) in 10% aqueous sodium hydroxide (115 ml) was heated at reflux for 1.5 hours. The reaction mixture was cooled then acidified with glacial acetic acid. The precipitated solid was collected by filtration, washed with water and dried *in vacuo* to afford a beige solid (0.542g).

20

MS (+ve ion electrospray) m/z 221 (MH⁺).

c) 4-Chloro-6-methoxy-[1,5]naphthyridine

The acid (10b) (6.82 g) was heated in quinoline (20ml) at reflux for 2 hours, the mixture was cooled and poured into ether (200ml) and the orange solid was filtered and washed with ether (5 x 200ml). A sample (3.87g) of the dried solid was treated with phosphorus oxychloride (30ml) at room temp for 3 hours, the solvent was removed *in vacuo* and the residue quenched with crushed ice (200g). The mixture was basified with ammonia solution and filtered. The solid was washed with dichloromethane (10 x 100ml), which was evaporated and chromatographed on silica gel (dichloromethane as eluent) to give a yellow solid (3.0g).

30

MS (+ve ion electrospray) m/z 195, 197 (MH⁺).

d) 4-Amino-6-methoxy-[1,5]naphthyridine

35 A solution of the chloro compound (10c) (2.0g) in pyridine (30ml) was treated with n-propylamine hydrochloride (6.0g) and the mixture heated at reflux for 16 hours. The reaction mixture was cooled and partitioned between water and ethyl acetate. The

aqueous phase was washed with ethyl acetate, the combined organics dried (Na_2SO_4) and the solvent removed under reduced pressure. Purification by chromatography on silica gel (5-10% methanol in dichloromethane) afforded a yellow solid (1.0g).

- 5 ^1H NMR (CDCl_3) δ : 4.05 (3H, s), 5.36 (2H, bs), 6.71 (1H, d, $J=5$ Hz), 7.08 (1H, d, $J=9$ Hz), 8.10 (1H, d, $J=9$ Hz), 8.40 (1H, d, $J=5$ Hz).
MS (+ve ion electrospray) m/z : 176 (MH^+).

e) N-(cis-1-tert-Butoxycarbonyl-3-(R/S)-ethoxycarbonyl-4-(S/R)-piperidyl)-N'-(6-methoxy-[1,5]-naphthyridin-4-yl)urea

- 10 To a solution of amine (10d) (0.5g) in chloroform (4ml) was added 1,1'-carbonyldiimidazole (0.76g) and dimethylaminopyridine (0.38g) and the solution was stirred at room temperature for 3.5 hours and evaporated to dryness. The product was heated at 100°C in dry DMF (7ml) containing the amine (9c) (0.85g), for 3 hours. Aqueous sodium carbonate was added and the mixture was extracted with
15 dichloromethane, dried over sodium sulfate, and evaporated to afford a foam. Chromatography on silica gel (ethyl acetate-hexane) gave an oil (0.928g).
MS (+ve ion electrospray) m/z 474 (MH^+).

- 20 f) N-(cis-3-(R/S)-Ethoxycarbonyl-4-(S/R)-piperidyl)-N'-(6-methoxy-[1,5]-naphthyridine-4-yl)urea

- The urea (10e) (0.92g) was treated with dichloromethane (20ml) and trifluoroacetic acid (30ml) at room temperature for 3 hours and evaporated to dryness. It was basified with sodium carbonate solution and evaporated to dryness. The solid was extracted three times with warm ethanol-chloroform (1:9) and evaporated to dryness to
25 afford a foam (0.80g).
MS (+ve ion electrospray) m/z 374 (MH^+).

g) Title compound

- 30 The amine (10f) (0.80g) in dry ethanol (20ml) was treated with heptaldehyde (0.26g) and sodium triacetoxyborohydride (0.82g) for 1 hour at room temperature. Sodium bicarbonate solution was added and the mixture was extracted with dichloromethane, dried over sodium sulfate, and evaporated to afford an oil. Chromatography on silica gel (ethyl acetate-hexane) gave the title compound (0.72g) as an oil.
35 MS (+ve ion electrospray) m/z 472 (MH^+).

The free base in dichloromethane was treated with 1 molar equivalent of oxalic acid in ether and the resulting solid was collected, triturated with ether, to afford the oxalate salt as a white solid.

5 Example 11. N-(cis-3-(R/S)-Aminocarbonyl-1-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxy-[1,5]-naphthyridin-4-yl)urea oxalate

The ester Example 10 (0.105g) in methanol (2ml) was heated with ammonia (3ml) and sodium cyanide (2mg) at 50°C (sealed bomb) for 3 days and evaporated to dryness. Chromatography on silica gel (ethyl acetate then methanol-dichloromethane) gave the
 10 title compound (0.024g), as the free base.
 MS (+ve ion electrospray) m/z 443 (MH⁺).
 The free base in dichloromethane-ether was converted to the oxalate salt in the normal manner, affording a white solid.

15 Example 12. [3R, 4R]-1-Heptyl-4-[3-(R/S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-3-(2-(R or S)-oxo-oxazolidin-5-yl)-piperidine

a) 9-O-Acetyl-(R/S)-10,11-epoxyquinine

A solution of Example 13b (57g, 140 mmol) in toluene (1 l) was treated with triphenyl phosphine (114g, 440 mmol) and diethylazodicarboxylate (80 ml, 510 mmol).
 20 The mixture was heated to reflux for 8h, the cooled and chromatographed eluting with methanol in dichloromethane to give the product as an oil (12g, 22%).
¹H NMR (CDCl₃) δ: 4.00 (3H, s), 6.50 (1H, m), 7.20-7.50 (3H, m), 8.03 (1H, d), 8.72 (1H, d). EI MH⁺ 383 C₂₂H₂₆N₂O₄ requires 382.

25 b) 9-O-Acetyl-(R/S)-11-azido-10-hydroxy-10,11-dihydroquinine

A solution of Example 12a (12g, 31.4 mmol) in N,N-dimethylformamide (100 ml) was treated with sodium azide (11.7g) and ammonium chloride (1g) and heated at 140°C for 7h. The mixture was evaporated and the residue partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic extract was dried and
 30 evaporated. The residue was chromatographed on silica eluting with methanol in dichloromethane affording the title compound as an orange foam (2.03g, 15%).
¹H NMR (CDCl₃) δ: 3.95 (3H, s), 6.50 (1H, m), 7.30-7.50 (3H, m), 8.00 (1H, d), 8.70 (1H, d). EI MH⁺ 426 C₂₂H₂₇N₅O₄ requires 425

35 c) 9-O-Acetyl-11-amino-10-hydroxy-10,11-dihydroquinine

Azide 12b (2.03 g, 4.8 mmol) in ethanol (30 ml) was hydrogenated over 10% palladium on charcoal for 2 hours. The mixture was filtered through celite and

evaporated. Chromatography on silica gel eluting with 5-20% methanol in dichloromethane containing 0.5-2% ammonia gave an orange oil (0.87g, 46%).

¹H NMR (CDCl₃) δ: 3.96 (3H,s), 6.50 (1H,d), 7.32-7.48 (3H,m), 8.02 (1H, d), 8.74 (1H,d), E.I. MH⁺ 400, C₂₂H₂₉N₃O₄ requires 399.

5

d) 5-(R/S)-{2-S-[R-acetoxy-(6-methoxyquinolin-4-yl)methyl]-5-R-quinuclidinyl}oxazolidin-2-one

A solution of amine 12c (0.65 g, 1.63 mmol), in dichloromethane (25 ml) was treated with triethylamine (0.56 ml, 4.0 mmol) and triphosgene (0.20 g, 0.67 mmol). After being stirred for 2 hours, further triphosgene (0.05 g, 0.16 mmol) was added and stirring continued for 1 hour. The mixture was diluted with dichloromethane and washed with sodium carbonate solution, dried and evaporated. Chromatography on silica gel eluting with 2-5% methanol in dichloromethane gave an off-white foam (0.54g, 66%),
¹H NMR (CDCl₃) δ: 3.96 (3H,s), 4.45(1H,m), 5.43 (1H,s), 6.47 (1H,d), 7.30-7.45 (3H,m), 8.02 (1H,d), 8.74 (1H,d). E.I. MH⁺ 426, C₂₃H₂₇N₃O₅ requires 425.

15

e) (3R,4R)-3-(2-Oxo-oxazolidin-5-yl)-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine

A solution of 12(d) (0.266 g, 0.63 mmol) in water/acetic acid (3 ml/0.3 ml) was heated to reflux for 2 days. The mixture was basified with 40% sodium hydroxide solution and extracted with ethyl acetate. The organic extracts were dried and evaporated to give the title compound as a yellow oil (105 mg),
¹H NMR (CDCl₃) δ: 3.94 (3H,s), 4.85(1H,m), 5.10 (1H,bs), 7.40 (1H,dd), 7.70 (1H, d), 7.85 (1H, d), 8.05 (1H,d), 8.90 (1H,d), E.I. MH⁺ 384 C₂₁H₂₅N₃O₄ requires 383.

25

f) (3R,4R)-1-Heptyl-3-(2-oxo-oxazolidin-5-yl)-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine

A solution of Example 12e(105 mg) in N,N-dimethylformamide (3 ml) was treated with potassium carbonate (0.14g) and heptyl iodide (0.2 ml). After 2h the reaction mixture was diluted with ethyl acetate and washed with sodium carbonate solution, brine, dried and evaporated. Chromatography on silica eluting with methanol in dichloromethane gave the title compound as a clear oil (70 mg, 23% over 2 stages),
¹H NMR (CDCl₃) δ: 0.85 (3H, t), 1.20-1.45 (10H, m), 3.94 (3H,s), 4.85(1H,m), 5.65 (1H,bs), 7.40 (1H,dd), 7.75 (1H, d), 7.90 (1H, d), 8.10 (1H,d), 8.90 (1H,d), E.I. MH⁺ 482 C₂₈H₃₉N₃O₄ requires 481.

35

g) Title compounds

A solution of Example 12f (42 mg, 0.09 mmol) in 2-propanol (5 ml) was treated with sodium borohydride (20 mg). After 2h the mixture was diluted with water and extracted with dichloromethane. The organic extract was dried and evaporated.

- Chromatography on silica eluting with methanol in dichloromethane afforded the title compounds as a clear oil (30 mg, 71%),
¹H NMR (CDCl₃) δ: 0.85 (3H, t), 1.20-1.45 (10H, m), 3.95 (3H, s), 4.85 (1H, m), 5.90 (1H, m), 5.90 (1H, s), 7.25 (1H, dd), 7.32 (1H, d), 7.55 (1H, dd), 8.00 (1H, d), 8.70 (1H, m), E.I. MH⁺ 484 C₂₈H₄₁N₃O₄ requires 483.

Example 13. [3R, 4R]-1-Heptyl-3-cyanomethyl-4-[3-(R/S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine

a) O-Acetylquinine

- A solution of quinine (97.2g, 300 mmol) in pyridine (300 ml) was treated with acetic anhydride (31 ml, 34g, 333mmol). After 4h the mixture was evaporated to dryness, azeotroping with water then toluene, affording the product as an oil which was used without further purification.
 EI MH⁺ 367, C₂₂H₂₆N₂O₃ requires 366

b) 9-O-Acetyl-10,11-dihydro-(R,S)-10,11-dihydroxyquinine

- A solution of Example 13a in acetone-water (400 ml-150 ml) was treated with osmium tetroxide (2g) in *tert*-butanol (50 ml). A solution of N-methylmorpholine N-oxide (49.1g, 420 mmol) was added. After 2 days more osmium tetroxide (1g) was added. After a further day sodium metabisulphite (30g) in water (100 ml) was added. After 2h the mixture was filtered and evaporated. The residue was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic extract was dried and chromatographed to give the diols as a white foam (109g, 91% over two steps).
 EI MH⁺ 401, C₂₂H₂₈N₂O₅ requires 400

c) 9-O-Acetyl-10-al-11-norquinine

- A solution of Example 13b (1.8g, 4.4 mmol) in pH7 phosphate buffer (30 ml) was treated at 0° C with a slurry of sodium periodate (1.9g, 8.8 mmol) in water (10 ml). After 0.5h, the mixture was extracted three times with chloroform. The chloroform extract was dried and evaporated to give the title compound as a white foam (1.1g, 65%).
¹H NMR (CDCl₃) δ: 3.95 (3H, s), 6.45 (1H, d), 7.35 (1H, m), 7.40 (1H, m), 8.05 (1H, d), 8.75 (1H, d), 9.75 (1H, s). EI MH⁺ 367, C₂₁H₂₄N₂O₄ requires 368

d) 10-Cyano-10,11-dihydro-11-norquinine

To a stirred suspension of potassium t-butoxide (6.28 g) in 1,2-dimethoxyethane (23 ml) kept below -30°C was added dropwise a solution of tosylmethyl isocyanide (5.62 g) in 1,2-dimethoxyethane (23 ml). After stirring for 20 minutes, a solution of Example 13c (10g) in 1,2-dimethoxyethane (32 ml) and THF (30 ml) was slowly added to the
5 reaction mixture at -50 to -60°C . After 50 minutes methanol (40ml) was added to the cold solution which was heated at reflux for 15 minutes. The solvent was removed under reduced pressure and saturated sodium bicarbonate solution added. The mixture was extracted with dichloromethane, washed with brine, dried over anhydrous magnesium sulphate, filtered and the solvent removed under reduced pressure. Chromatography on
10 silica gel eluting with 5% methanol in dichloromethane gave a yellow foam (3.58g, 39 %).

$^1\text{H NMR}$ (CDCl_3) δ : 8.70 (d, 1H), 8.00 (d, 1H), 7.54 (d, 1H), 7.34 (d, 1H), 7.19 (d, 1H), 5.62 (s, 1H), 3.88 (s, 3H), 3.45-3.6 (m, 1H), 3.15-3.25 (m, 1H), 3.00-3.15 (m, 1H), 2.55-3.25 (m, 1H), 2.38-2.50 (m, 1H), 2.18-2.25 (m, 2H), 2.10-1.80 (m, 4H), 1.35-1.6 (m, 2H). EI MH^+
15 338 $\text{C}_{20}\text{H}_{23}\text{N}_3\text{O}_2$ requires 337.

e) [3R,4R]-3-Cyanomethyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine

A solution of Example 13d (3.58 g) in glacial acetic acid (4 ml) and water (40 ml) was heated at reflux under a flow of argon for 36 hours. The reaction mixture was taken
20 to pH12 with sodium hydroxide solution. The mixture was extracted into ethyl acetate, dried over anhydrous magnesium sulphate, filtered and the solvent removed under reduced pressure. Chromatography on silica gel eluting with 5 to 10 % methanol in dichloromethane gave the compound as an oil (0.830 g, 23%).

$^1\text{H NMR}$ (CDCl_3) δ : 8.89 (d, 1H), 8.07 (d, 1H), 7.85 (d, 1H), 7.61 (d, 1H), 7.41 (d, 1H),
25 3.95 (s, 3H), 3.20-3.01 (m, 4 H), 2.83-2.58 (m, 3 H), 2.43-2.34 (m, 1H), 2.00-2.18 (m, 1H), 1.85-1.70 (m, 3H), 1.65-1.50 (m, 1H), 1.45-1.25 (m, 1H).
 EI MH^+ 338 $\text{C}_{20}\text{H}_{23}\text{N}_3\text{O}_2$ requires 337.

f) [3R,4R]-1-Heptyl-3-cyanomethyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine
30

Amine 13e (0.830g) was heptylated according to the method for example 1h to give the compound as an oil (0.856g, 80%).

$^1\text{H NMR}$ (CDCl_3) δ : 8.89 (d, 1H), 8.07 (d, 1H), 7.85 (d, 1H), 7.61 (d, 1H), 7.41 (d, 1H),
35 3.96 (s, 3H), 3.15-2.96 (m, 3H), 2.88-2.70 (m, 2H), 2.45-1.90 (m, 6H), 1.80-1.20 (m, 15H),
0.89 (t, 3H)
 EI MH^+ 436 $\text{C}_{27}\text{H}_{37}\text{N}_3\text{O}_2$ requires 435.

g) Title compound

A solution of ketone 13f (0.738g) in isopropanol (10 ml) was treated at 0°C with sodium borohydride (0.064g). The mixture allowed to warm to room temperature. After 3 hours, water (20 ml) was added and the mixture extracted with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulphate, filtered and the solvent removed under reduced pressure. Chromatography on silica gel eluting with 1 to 5 % methanol in dichloromethane gave the title compound as a yellow oil (0.595 g, 80 %).
¹H NMR (CDCl₃) δ: 8.75 (d,1H), 8.05 (d,1H), 7.50 (d,1H), 7.37 (d,1H), 7.25 (d, 1H), 5.40 (m,1H), 3.94 (s,3H), 3.05-2.55 (m,3H), 2.45-2.15 (m,3H), 2.10-1.75 (m,5H), 1.75-1.10 (m,15H), 0.88 (t,3H). EI MH⁺ 438 C₂₇H₃₉N₃O₂ requires 437.

Example 14. [3R, 4R]-1-Heptyl-3-cyanomethyl-4-(2-(R)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)piperidine

a) [3R,4R]-1-Heptyl-3-cyanomethyl-4-[2(R),3(R)-oxiranyl-3-(6-methoxyquinolin-4-yl)propyl)piperidine

A solution of 13d (3.2 g) in toluene (30 ml) and N,N-dimethylformamide (3ml) was heated at 80°C with heptyl bromide (1.65ml) overnight under a stream of argon. Starting material was still present so heptyl iodide (0.8 ml) was added and the mixture heated at 80°C for 2 hours. The solvent was removed under reduced pressure and the residue was dissolved in *t*-butanol (40ml) and THF (10 ml). Potassium *t*-butoxide (1M in THF, 11ml) was added and the mixture heated at reflux under a stream of argon for 1 hour. The mixture was allowed to cool to room temperature, silica added and the solvent removed under reduced pressure. Chromatography on silica gel (dry loaded) eluting with 1 to 5 % methanol in dichloromethane gave the compound as a brown oil (1.72 g, 42%).
¹H NMR (CDCl₃) δ: 8.75 (d,1H), 8.07 (d,1H), 7.43 (d,1H), 7.27 (m,2H), 4.18 (s,1H), 3.95 (s,1H), 3.05-2.65 (m,4H), 2.40-1.15 (m,23H), 0.90 (t,3H)
EI MH⁺ 436 C₂₇H₃₇N₃O₂ requires 435.

b) Title compound

A solution of oxirane 14a (1.32 g) in ethanol (30 ml), was treated with 10% palladium on charcoal (0.85 g) and the mixture hydrogenated at atmospheric pressure for 4 hours. The mixture was filtered through a small plug of celite and the solvent removed under reduced pressure. Chromatography on silica gel eluting with 2% methanol in dichloromethane gave the target compound as a brown oil (0.462 g, 35 %).
¹H NMR (CDCl₃) δ: 8.37 (d,1H), 7.84 (d,1H), 7.28 (m,2H), 7.15 (d,1H), 4.24 (m,1H), 3.95 (s,3H), 3.20-3.30 (m,1H), 3.10-2.60 (m,5H), 2.45-1.10 (m,21H), 0.86 (t,3H).
EI MH⁺ 438 C₂₇H₃₉N₃O₂ requires 437.

The following compound Examples were prepared following the procedures described in the synthetic methodology section and previous preparative Examples:


5 **Example 15. N-(cis-3-(R/S)-Carboxy-1-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxyquinolin-4-yl)urea tris-trifluoroacetate**
MS (+ve ion electrospray) m/z 443 (MH+).

10 **Example 16. cis-3-(R/S)-Ethoxycarbonyl-1-heptyl-4-(S/R)-(6-methoxyquinolin-4-yl)aminocarbonyloxypiperidine**
MS (+ve ion electrospray) m/z 472 (MH+).

15 **Example 17. cis-3-(R/S)-Carboxy-1-heptyl-4-(S/R)-(6-methoxyquinolin-4-yl)aminocarbonyloxypiperidine**
MS (+ve ion electrospray) m/z 444 (MH+).

The following compounds were prepared following the procedures described in the synthetic methodology section and previous preparative Examples

TABLE 1



5

Example	A-B	n	R ¹	D	R ₃	R ₄
18	CH ₂ CH ₂	1	CH ₃ O	C	CH ₂ CN	n-heptyl
19	CH(NH ₂)CH ₂	1	CH ₃ O	C	CH ₂ CN	n-heptyl
20	CH ₂ CH ₂	1	CH ₃ O	C	CH ₂ COOH	5-methylhexyl
21	CH(N ₃)CH ₂	1	CH ₃ O	C	CH ₂ CN	n-heptyl
22	CH ₂ CH ₂	1	CH ₃ O	C	CONH ₂	n-heptyl
23	CH ₂ CH ₂	1	CH ₃ O	C	CH ₂ COOH	n-hexyl
24	CO.CH ₂	1	CH ₃ O	C	CH ₂ CN	n-heptyl
25	CH ₂ CH ₂	1	CH ₃ O	C	CH ₂ CH(CH ₃)COOH	n-heptyl
26	CH ₂ CH ₂	1	CH ₃ O	C	CH ₂ COOH	cinnamyl
27	CH ₂ CH ₂	1	CH ₃ O	C	CH ₂ COOH	3-phenylpropyl
28	CH(OH)CH ₂	1	CH ₃ O	C	CH ₂ COOH	n-heptyl
29	CH(NH ₂)CH ₂	1	CH ₃ O	C	CH ₂ COOH	n-heptyl
30	CH(OH)CH ₂	1	CH ₃ O	C	CH(OH)COOH	n-heptyl
31	CO.CH ₂	1	CH ₃ O	C	CH(OH)COOH	n-heptyl
32	CH ₂ CH(OH)	1	CH ₃ O	C	CH ₂ COOH	n-heptyl
33	NHCO	1	CH ₃ O	N	CH ₂ COOH	n-heptyl
34	CH ₂ CH ₂	1	OH	C	CH ₂ COOH	n-heptyl
35	NHCOO	0	CH ₃ O	C	CONH ₂	n-heptyl
36	oxirane	1	CH ₃ O	C	CH ₂ CN	n-heptyl

Biological Activity

The MIC ($\mu\text{g/ml}$) of test compounds against various organisms was determined: *S. aureus* Oxford, *S. aureus* WCUH29, *S. aureus* Carter 37, *E. faecalis* I, *M. catarrhalis* Ravasio, *S. pneumoniae* R6.


- 5 Examples 1 to 8, 12 to 14, 18 to 25, 33 and 36 have an MIC of less than or equal to $1\mu\text{g/ml}$ against one or more of the above range of gram positive and gram negative bacteria.

- 10 Examples 11, 17, 26 to 32, 34 and 35 showed an MIC of less than or equal to $16\mu\text{g/ml}$ against one or more of the above range of gram positive and gram negative bacteria.

Examples 9, 10, 15 and 16 showed an MIC of less than or equal to $64\mu\text{g/ml}$ against one or more of the above range of gram positive and gram negative bacteria.

Claims

1. A method of treatment of bacterial infections in mammals, which method comprises the administration to a mammal in need of such treatment of an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative thereof:



(I)

wherein:

10

one of Z¹, Z², Z³, Z⁴ and Z⁵ is N or CR^{1a} and the remainder are CH;

R¹ is selected from hydroxy; (C₁₋₆) alkoxy optionally substituted by (C₁₋₆)alkoxy, amino, piperidyl, guanidino or amidino optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups, NH₂CO, hydroxy, thiol, (C₁₋₆)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋₆)alkylsulphonyloxy; (C₁₋₆)alkoxy-substituted (C₁₋₆)alkyl; halogen; (C₁₋₆)alkyl; (C₁₋₆)alkylthio; trifluoromethyl; nitro; azido; acyl; acyloxy; acylthio; (C₁₋₆)alkylsulphonyl; (C₁₋₆)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups, or when one of Z¹, Z², Z³, Z⁴ and Z⁵ is N, R¹ may instead be hydrogen;

25

R^{1a} is selected from hydrogen and the groups listed above for R¹;

R³ is in the 2- or 3-position and is:

carboxy; (C₁₋₆)alkoxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, trifluoromethylsulphonyl, (C₁₋₆)alkenylsulphonyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R¹⁰; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-

thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R¹⁰; or 5-oxo-1,2,4-oxadiazol-3-yl; or

R³ is in the 2- or 3-position and is (C₁₋₄)alkyl or ethenyl substituted with any of the groups listed above for R³ and 0 to 2 groups R¹² independently selected from:

- 5 thiol; halogen; (C₁₋₆)alkylthio; trifluoromethyl; azido; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; (C₂₋₆)alkenylcarbonyl; hydroxy optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylcarbonyl or (C₂₋₆)alkenylcarbonyl; amino optionally mono- or disubstituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, (C₂₋₆)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; oxo; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or (C₁₋₆)aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl;
- 10 provided that when R³ is disubstituted with hydroxy or amino and carboxy containing substituents these may optionally together form a cyclic ester or amide linkage, respectively;
- 15 and provided that R³ is other than (C₁₋₄)alkyl or ethenyl substituted by (C₁₋₆)alkoxycarbonyl or aminocarbonyl optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl and 0 to 2 groups R¹²;
- 20 wherein R¹⁰ is selected from (C₁₋₄)alkyl; (C₂₋₄)alkenyl; aryl; a group R¹² as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, trifluoromethylsulphonyl, (C₁₋₆)alkenylsulphonyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; cyano; or tetrazolyl;
- 25 wherein R¹⁰ is selected from (C₁₋₄)alkyl; (C₂₋₄)alkenyl; aryl; a group R¹² as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, trifluoromethylsulphonyl, (C₁₋₆)alkenylsulphonyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; cyano; or tetrazolyl;
- 30 wherein R¹⁰ is selected from (C₁₋₄)alkyl; (C₂₋₄)alkenyl; aryl; a group R¹² as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, trifluoromethylsulphonyl, (C₁₋₆)alkenylsulphonyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; cyano; or tetrazolyl;
- 35 wherein R¹⁰ is selected from (C₁₋₄)alkyl; (C₂₋₄)alkenyl; aryl; a group R¹² as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, trifluoromethylsulphonyl, (C₁₋₆)alkenylsulphonyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; cyano; or tetrazolyl;

R⁴ is a group -CH₂-R⁵ in which R⁵ is selected from:

(C₃₋₁₂)alkyl; hydroxy(C₃₋₁₂)alkyl; (C₁₋₁₂)alkoxy(C₃₋₁₂)alkyl; (C₁₋₁₂)alkanoyloxy(C₃₋₁₂)alkyl; (C₃₋₆)cycloalkyl(C₃₋₁₂)alkyl; hydroxy-, (C₁₋₁₂)alkoxy- or (C₁₋₁₂)alkanoyloxy-(C₃₋₆)cycloalkyl(C₃₋₁₂)alkyl; cyano(C₃₋₁₂)alkyl; (C₂₋₁₂)alkenyl; (C₂₋₁₂)alkynyl; tetrahydrofuryl; mono- or di-(C₁₋₁₂)alkylamino(C₃₋₁₂)alkyl; acylamino(C₃₋₁₂)alkyl; (C₁₋₁₂)alkyl- or acyl-aminocarbonyl(C₃₋₁₂)alkyl; mono- or di-(C₁₋₁₂)alkylamino(hydroxy) (C₃₋₁₂)alkyl; optionally substituted phenyl(C₁₋₂)alkyl, phenoxy(C₁₋₂)alkyl or phenyl(hydroxy)(C₁₋₂)alkyl; optionally substituted diphenyl(C₁₋₂)alkyl; optionally substituted phenyl(C₂₋₃)alkenyl; optionally substituted benzoyl or benzoylmethyl; optionally substituted heteroaryl(C₁₋₂)alkyl; and optionally substituted heteroaryl or heteroarylmethyl;

n is 0, 1 or 2;

either A-B is NHC(O)NH or NHC(O)O, or

15

A is NR¹¹, O, S(O)_x or CR⁶R⁷ and B is NR¹¹, O, S(O)_x or CR⁸R⁹ where x is 0, 1 or 2 and wherein:

each of R⁶ and R⁷ R⁸ and R⁹ is independently selected from: H; thiol; (C₁₋₆)alkylthio; halo; trifluoromethyl; azido; (C₁₋₆)alkyl; (C₂₋₆)alkenyl; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; (C₂₋₆)alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or (C₁₋₆)aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₁₋₆)alkenyl; or R⁶ and R⁸ together represent a bond and R⁷ and R⁹ are as above defined; or R⁶ and R⁸ together represent -O- and R⁷ and R⁹ are both hydrogen; or R⁶ and R⁷ or R⁸ and R⁹ together represent oxo; and each R¹¹ is independently H, trifluoromethyl, (C₁₋₆)alkyl, (C₁₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₁₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl or (C₁₋₆)alkenyl and optionally further substituted by (C₁₋₆)alkyl or (C₁₋₆)alkenyl;

provided that A and B cannot both be selected from NR¹¹, O and S(O)_x and when one of A and B is CO the other is not CO, O or S(O)_x.

35

2. A compound of formula (IA) or a pharmaceutically acceptable derivative thereof which is a compound of formula (I) as defined in claim 1 wherein R³ is other than (C₁₋₆)alkoxycarbonyl; optionally substituted aminocarbonyl, CN or COOH.
3. A compound according to claim 2 wherein Z⁵ is CH or N and Z¹-Z⁴ are each
5 CH.
4. A compound according to claim 2 or 3 wherein R¹ is methoxy, amino- or guanidino-(C₃₋₅)alkyloxy, guanidino(C₃₋₅)alkyloxy, piperidyl(C₃₋₅)alkyloxy, nitro or fluoro, and R^{1a} is hydrogen.
5. A compound according to any of claims 2 to 4 wherein R³ is in the 3-position and
10 is CH₂CO₂H or 2-oxo-oxazolidinyl.
6. A compound according to any of claims 2 to 5 wherein AB(CH₂)_n is (CH₂)₃.
7. A compound according to any of claims 2 to 6 wherein R⁴ is (C₅₋₁₀)alkyl, unsubstituted phenyl(C₂₋₃)alkyl or unsubstituted phenyl(C₃₋₄)alkenyl.
8. A compound of formula (I) as defined in claim 1 selected from:
15 [3R, 4R]-1-Heptyl-3-(1-(R or S)-hydroxy-2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R, 4R]-1-Heptyl-3-(2-(R or S)-oxo-oxazolidin-5-yl)-4-[3-(6-methoxyquinolin-4-yl)propyl] piperidine;
[3R, 4R]-1-Heptyl-3-(2-cyanoethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine;
20 [3R, 4R]-1-Heptyl-3-(3-carboxyethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine;
[3R, 4R]-1-Heptyl-3-carboxy-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine;
[3R, 4R]-1-Heptyl-3-(carboxymethyl)-4-[3-(6-methoxyquinolin-4-yl) propyl] piperidine;
[3R, 4R]-1-Heptyl-3-(1-(R or S)-hydroxy-2-carboxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
25 [3R, 4R]-1-Heptyl-3-(2-(*E*)-carboxyethenyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
N-(cis-3-(R/S)-Ethoxycarbonyl-1-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxyquinolin-4-yl)urea;
N-(cis-3-(R/S)-Ethoxycarbonyl-1-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxy-[1,5]-
30 naphthyridin-4-yl)urea;
N-(cis-3-(R/S)-Aminocarbonyl-1-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxy-[1,5]-naphthyridin-4-yl)urea;
[3R, 4R]-1-Heptyl-4-[3-(R/S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-3-(2-(R or S)-oxo-oxazolidin-5-yl)-piperidine;
35 [3R, 4R]-1-Heptyl-3-cyanomethyl-4-[3-(R/S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-1-Heptyl-3-cyanomethyl-4-(2-(R)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl)piperidine;

N-(cis-3-(R/S)-Carboxy-1-heptyl-4-(S/R)-piperidyl)-N'-(6-methoxyquinolin-4-yl)urea;

cis-3-(R/S)-Ethoxycarbonyl-1-heptyl-4-(S/R)-(6-methoxyquinolin-4-yl)aminocarbonyl-oxypiperidine;


cis-3-(R/S)-Carboxy-1-heptyl-4-(S/R)-(6-methoxyquinolin-4-yl)aminocarbonyl-oxypiperidine;

a compound 18-36 from Table 1;


or a pharmaceutically acceptable derivative of any of the foregoing compounds.

9. A process for preparing compounds of formula (IA) as defined in claim 2; or a pharmaceutically acceptable derivative thereof, which process comprises:

(a) reacting a compound of formula (IV) with a compound of formula (V):



(IV)



(V)


wherein Z¹, Z², Z³, Z⁴ and Z⁵, m, n, R¹, R², R³ and R⁴ are as defined in formula (I), and X and Y may be the following combinations:

- (i) X is M and Y is CH₂CO₂R^x
- (ii) X is CO₂RY and Y is CH₂CO₂R^x
- (iii) one of X and Y is CH=SPh₂ and the other is CHO
- (iv) X is CH₃ and Y is CHO
- (v) X is CH₃ and Y is CO₂R^x
- (vi) X is CH₂CO₂RY and Y is CO₂R^x
- (vii) X is CH=PR^z₃ and Y is CHO
- (viii) X is CHO and Y is CH=PR^z₃
- (ix) X is halogen and Y is CH=CH₂
- (x) one of X and Y is COW and the other is NHR^{11'} or NCO
- (xi) one of X and Y is (CH₂)_p-V and the other is (CH₂)_qNHR^{11'}, (CH₂)_qOH, (CH₂)_qSH or (CH₂)_qSCOR^x where p+q=1
- (xii) one of X and Y is CHO and the other is NHR^{11'}
- (xiii) one of X and Y is OH and the other is -CH=N₂

in which V and W are leaving groups, R^X and R^Y are (C_{1-6}) alkyl and R^Z is aryl or (C_{1-6}) alkyl, or


(xiv) X is NCO, Y is OH or NH_2 ;

- 5 (b) reacting a compound of formula (IV) with a compound of formula (Vb):




- 10 wherein Z^1, Z^2, Z^3, Z^4 and Z^5 , m, n, R^1, R^2, R^3 and R^4 are as defined in formula (I), X is $CH_2NHR^{11'}$ and Y is CHO or COW or X is CH_2OH and Y is $-CH=N_2$;

- (c) rearranging a compound of formula (II):



- 15 to give a compound of formula (III) which is a compound of formula (I) where Z^1-Z^5 are CH, n is 1, A-B is $COCH_2$ and R^2 is H, or a compound of formula (VII) which is a compound of formula (I) where n is 1, A-B is $CHOHCH_2$ or CH_2CHOH and R^2 is H; or

- (d) photooxygenating a compound of formula (VI):



20 in which Z^1-Z^5 are Z^1-Z^5 or groups convertible thereto, $R^{11'}, R^1, R^2, R^3$ and R^4 are R^{11}, R^1, R^2, R^3 and R^4 or groups convertible thereto, and thereafter optionally or as

necessary converting $R^{11'}$, $R^{1'}$, $R^{2'}$, $R^{3'}$ and $R^{4'}$ to R^{11} , R^1 , R^2 , R^3 and R^4 , converting $Z^{1'}$ - $Z^{5'}$ to Z^1 - Z^5 , converting A-B to other A-B, interconverting R^{11} , R^1 , R^2 , R^3 and/or R^4 and forming a pharmaceutically acceptable derivative thereof.

- 5 10. A pharmaceutical composition comprising a compound of formula (IA) as defined in claim 2, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
11. The use of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for use in the treatment
- 10 of bacterial infections in mammals.
12. A pharmaceutical composition for use in the treatment of bacterial infections in mammals comprising a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/00350

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/06 C07D401/12 C07D401/14 A61K31/445 A61K31/47
A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 99 37635 A (SMITHKLINE BEECHAM PLC) 29 July 1999 (1999-07-29) claims 1-16	1-12
A	WO 98 57931 A (SEPRACOR INC.) 23 December 1998 (1998-12-23) claims 1-194	1-12
A	WO 98 57952 A (SEPRACOR INC.) 23 December 1998 (1998-12-23) claims 1-194	1-12
Y	WO 96 39145 A (RHONE-POULENC RORER PHARMACEUTICALS INC.) 12 December 1996 (1996-12-12) cited in the application claims 1-20	1-12

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 April 2000

Date of mailing of the international search report

08/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

Int. J. Appl. No.

PCT/EP 00/00350

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 97 03069 A (GLAXO GROUP LTD.) 30 January 1997 (1997-01-30) cited in the application claims 1-18</p> <p>-----</p>	1-12

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/00350

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9937635 A	29-07-1999	AU 2717899 A	09-08-1999
WO 9857931 A	23-12-1998	AU 7979798 A	04-01-1999
		AU 8258698 A	04-01-1999
		EP 0991623 A	12-04-2000
		NO 996269 A	16-02-2000
		WO 9857952 A	23-12-1998
WO 9857952 A	23-12-1998	AU 7979798 A	04-01-1999
		AU 8258698 A	04-01-1999
		EP 0991623 A	12-04-2000
		NO 996269 A	16-02-2000
		WO 9857931 A	23-12-1998
WO 9639145 A	12-12-1996	US 5721237 A	24-02-1998
		AU 696456 B	10-09-1998
		AU 6104496 A	24-12-1996
		BR 9608638 A	29-06-1999
		CA 2223016 A	12-12-1996
		CZ 9703503 A	18-03-1998
		EP 0831831 A	01-04-1998
		HU 9802702 A	29-03-1999
		JP 11507355 T	29-06-1999
		SI 9620092 A	31-08-1998
		SK 166397 A	03-06-1998
WO 9703069 A	30-01-1997	AU 6613996 A	10-02-1997
		EP 0843671 A	27-05-1998
		HR 960316 A	28-02-1998
		JP 11508906 T	03-08-1999